Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.11 - neprilysin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis, Respiratory
Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.
Acne Vulgaris
Neuropeptides and sebaceous glands.
New aspects in acne inflammation.
Sebaceous glands in acne patients express high levels of neutral endopeptidase.
Acquired Immunodeficiency Syndrome
Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomized crossover study.
Acute Coronary Syndrome
Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
Acute Kidney Injury
Down regulation of kidney neutral endopeptidase mRNA, protein and activity during acute renal failure: possible mechanism for ischemia-induced acute renal failure in rats?
Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure.
Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin inhibitors.
Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
Urinary neprilysin for early detection of acute kidney injury after cardiac surgery: A prospective observational study.
Acute Lung Injury
Expression of neutral endopeptidase activity during clinical and experimental acute lung injury.
Adenocarcinoma
Characterization of the promoter region of the rat neprilysin gene.
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Adenomyosis
Expression of aminopeptidase N and neutral endopeptidase on the endometrial stromal cells in endometriosis and adenomyosis.
Airway Obstruction
Effects of inhaled or intravenous thiorphan on substance P-induced airway obstruction.
Alagille Syndrome
Lack of hepatocellular CD10 along bile canaliculi is physiologic in early childhood and persistent in Alagille syndrome.
Albuminuria
Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.
Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy.
Alzheimer Disease
(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.
5-HIAA induces neprilysin to ameliorate pathophysiology and symptoms in a mouse model for Alzheimer's disease.
A highly sensitive peptide substrate for detecting two Abeta-degrading enzymes: neprilysin and insulin-degrading enzyme.
A monoclonal antibody to common acute lymphoblastic leukemia antigen (neutral endopeptidase) immunostains senile plaques in the brains of patients with Alzheimer's disease.
A novel system for in vivo neprilysin gene delivery using a syringe electrode.
Accumulation of Insoluble Amyloid-? in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities.
Accumulation of murine amyloid-? mimics early Alzheimer's disease.
Activating AhR alleviates cognitive deficits of Alzheimer's disease model mice by upregulating endogenous A? catabolic enzyme Neprilysin.
Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels.
Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease.
Association between neprilysin polymorphisms and sporadic Alzheimer's disease.
Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease.
Associations of Neprilysin Activity in CSF with Biomarkers for Alzheimer's Disease.
Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis.
Cell Surface Expression of the Major Amyloid-? Peptide (A?)-degrading Enzyme, Neprilysin, Depends on Phosphorylation by Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK) and Dephosphorylation by Protein Phosphatase 1a.
Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease.
Co-Administration of TiO2 Nanowired Mesenchymal Stem Cells with Cerebrolysin Potentiates Neprilysin Level and Reduces Brain Pathology in Alzheimer's Disease.
Combined risk effects of IDE and NEP gene variants on Alzheimer disease.
Complementary distributions of amyloid-beta and neprilysin in the brains of dogs and cats.
Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.
Convection-Enhanced Delivery of Neprilysin: A Novel Amyloid-?-Degrading Therapeutic Strategy.
Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy.
Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.
Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging.
Design of Peptide Substrate for Sensitively and Specifically Detecting Two A?-Degrading Enzymes: Neprilysin and Angiotensin-Converting Enzyme.
Developmental Profile of Brain Neprilysin Expression Correlates with Olfactory Behaviour of Rats.
Dinucleotide repeat polymorphisms in the neprilysin gene are not associated with sporadic Alzheimer's disease.
Distinct subcellular patterns of neprilysin protein and activity in the brains of Alzheimer's disease patients, transgenic mice and cultured human neuronal cells.
DNA methylation level of the neprilysin promoter in Alzheimer's disease brains.
Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.
Dynamic alteration of neprilysin and endothelin-converting enzyme in age-dependent APPswe/PS1dE9 mouse model of Alzheimer's disease.
Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions.
Effects of HNE-modification induced by Abeta on neprilysin expression and activity in SH-SY5Y cells.
ENDOCANNABINOIDS RECEPTORS MEDIATED CENTRAL AND PERIPHERAL EFFECTS (REVIEW).
Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease.
Estrogen Regulation of the Neprilysin Gene Through A Hormone-Responsive Element.
Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid beta peptide.
Evaluation of neprilysin sequence variation in relation to CSF ?-Amyloid levels and Alzheimer disease risk.
Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease.
Expression of Somatostatin, Cortistatin, and Their Receptors, as well as Dopamine Receptors, but not of Neprilysin, are Reduced in the Temporal Lobe of Alzheimer's Disease Patients.
Extracellular Vesicles as a Neprilysin Delivery System Memory Improvement in Alzheimer's Disease.
Genetic variation in MME in relation to neprilysin protein and enzyme activity, A? levels, and Alzheimer's disease risk.
Genetically engineered exosomes display RVG peptide and selectively enrich a neprilysin variant: a potential formulation for the treatment of Alzheimer's disease.
Histone Acetylation Regulates Natriuretic Peptides and Neprilysin Gene Expressions in Diabetic Cardiomyopathy and Nephropathy.
Identification of the sites of 4-hydroxy-2-nonenal and neprilysin adduction using a linear trap quadrapole Velos Pro-Orbitrap Elite mass spectrometer.
Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid.
Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid Beta and impairment of learning and memory.
Lack of association of neprilysin gene polymorphisms with Alzheimer's disease in a southern Chinese community.
Lack of association of neprilysin polymorphism with Alzheimer's disease and Alzheimer's disease-type neuropathological changes.
Limitations of Sacubitril/Valsartan in the Management of Heart Failure.
Locomotor and geotactic behavior of Drosophila melanogaster over-expressing neprilysin 2.
Long-term neprilysin inhibition - implications for ARNIs.
Loss of neprilysin alters protein expression in the brain of Alzheimer's disease model mice.
Mercury reduces the enzymatic activity of neprilysin in differentiated SH-SY5Y cells.
Meta-analysis of expression and function of neprilysin in Alzheimer's disease.
Meta-analysis of the association between two neprilysin gene polymorphisms and Alzheimer's disease.
miR-26b inhibits total neurite outgrowth, promotes cells apoptosis and downregulates neprilysin in Alzheimer's disease.
Mitochondria-targeted catalase reduces abnormal APP processing, amyloid ? production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.
Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons.
Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease.
Neprilysin activity and expression are controlled by nicastrin.
Neprilysin and A? Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease.
Neprilysin and amyloid beta peptide degradation.
Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity.
Neprilysin Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese.
Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease.
Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.
Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease.
Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation.
Neprilysin Inhibits Coagulation through Proteolytic Inactivation of Fibrinogen.
Neprilysin is poorly expressed in the prefrontal cortex of aged dogs with cognitive dysfunction syndrome.
Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?
Neprilysin-Like Activity Correlates with CSF-Tau and Phospho-Tau in Patients with Alzheimer's Disease.
Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function.
Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease.
Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.
Nitric Oxide Decreases the Enzymatic Activity of Insulin Degrading Enzyme in APP/PS1 Mice.
No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer's disease patients.
Oxidized neprilysin in aging and Alzheimer's disease brains.
Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease.
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
Pharmacological Heart Failure Therapy in Children: Focus on Inotropic Support.
Polyhydroxycurcuminoids but not curcumin upregulate neprilysin and can be applied to the prevention of Alzheimer's disease.
Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients.
Possible increased risk for Alzheimer's disease associated with neprilysin gene.
Possible role of resveratrol targeting estradiol and neprilysin pathways in lipopolysaccharide model of Alzheimer disease.
Possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade.
Proteinase dysbalance in pathology: the neprilysin (NEP) and angiotensin-converting enzyme (ACE) families.
Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice.
Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide.
Regulation of Neprilysin Activity and Cognitive Functions in Rats After Prenatal Hypoxia.
Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain.
Retrograde transport of masseter muscle-derived neprilysin to hippocampus.
Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.
Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan.
The antioxidant xanthorrhizol prevents amyloid-?-induced oxidative modification and inactivation of neprilysin.
The Association between Neprilysin gene polymorphisms and Alzheimer's disease in Tibetan population.
The characteristics of astrocyte on A? clearance altered in Alzheimer's disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate.
The extracellular matrix enriched with membrane metalloendopeptidase and insulin-degrading enzyme suppresses the deposition of amyloid-beta peptide in Alzheimer's disease cell models.
Up-regulation of neprilysin mediates the protection of fructo-oligosaccharides against Alzheimer's disease.
Valproic acid reduces neuritic plaque formation and improves learning deficits in APP(Swe) /PS1(A246E) transgenic mice via preventing the prenatal hypoxia-induced down-regulation of neprilysin.
Wide-Ranging Effects on the Brain Proteome in a Transgenic Mouse Model of Alzheimer's Disease Following Treatment with a Brain-Targeting Somatostatin Peptide.
[Association of the neprilysin and apolipoprotein E gene polymorphisms with Alzheimer's disease in Xinjiang Uygur population.]
[Effect of Electroacupuncture on Levels of ?-amyloid and Neprilysin Proteins in the Cerebral Cortex of Alzheimer's Disease Mice Based on "Mutual Assistance of Kidney and Brain" Theory].
[Effects of Naoerkang on expressions of beta-amyloid peptide 1-42 and neprilysin in hippocampus in a rat model of Alzheimer's disease]
Amyloidosis
Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis.
Cell Surface Expression of the Major Amyloid-? Peptide (A?)-degrading Enzyme, Neprilysin, Depends on Phosphorylation by Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK) and Dephosphorylation by Protein Phosphatase 1a.
Neprilysin deficiency-dependent impairment of cognitive functions in a mouse model of amyloidosis.
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.
Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila.
Update in recent clinical trials in heart failure.
Anaphylaxis
Phosphoramidon augments contraction of guinea pig tracheal smooth muscle induced by histamine and leukotriene-D4.
Role of neurogenic inflammation in antigen-induced vascular extravasation in guinea pig trachea.
Anemia
Update in recent clinical trials in heart failure.
Anemia, Hypochromic
First Report of Capsicum chlorosis virus Causing Yellow Stripes on Calla Lilies in Taiwan
First Report of Capsicum chlorosis virus Causing Yellow Stripes on Calla Lilies in Taiwan.
First Report of Capsicum chlorosis virus Infecting Amaryllis and Blood Lily in Taiwan
First Report of Capsicum chlorosis virus Infecting Amaryllis and Blood Lily in Taiwan.
First Report of Capsicum chlorosis virus Infecting Chromolaena odorata L. in Yunnan, China.
Identification of Common Epitopes on a Conserved Region of NSs Proteins Among Tospoviruses of Watermelon silver mottle virus Serogroup
Identification of Common Epitopes on a Conserved Region of NSs Proteins Among Tospoviruses of Watermelon silver mottle virus Serogroup.
Mosaic Disease of Calla Lily Caused by a New Potyvirus in Taiwan.
Mosaic disease of calla lily caused by a new potyvirus in Taiwan.
Serological relationship between Melon yellow spot virus and Watermelon silver mottle virus and differential detection of the two viruses in cucurbits.
Anemia, Iron-Deficiency
Update in recent clinical trials in heart failure.
Aneurysm, Dissecting
Simplified technique for hemi-arch replacement during open distal anastomosis: the "calla" method.
Angioedema
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Angioedema induced by cardiovascular drugs: new players join old friends.
Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.
Angioedema with renin angiotensin system drugs and neutral endopeptidase inhibitors.
Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.
Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact.
Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema.
Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-Like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation In The Rat.
Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary.
Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI).
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Neprilysin Inhibitors and Bradykinin.
Novel therapeutic targets for hypertension.
Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
[Neprilysin inhibition and chronic kidney disease].
Aortic Aneurysm, Abdominal
Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs.
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Aortic Valve Insufficiency
Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats.
Aortic Valve Stenosis
Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure.
Arrhythmias, Cardiac
Angiotensin receptor-neprilysin inhibitior (thiorphan/irbesartan) decreased ischemia-reperfusion induced ventricular arrhythmias in rat; in vivo study.
Arthritis
D-phenylalanine and other enkephalinase inhibitors as pharmacological agents: implications for some important therapeutic application.
Elevated synovial tissue concentration of the common acute lymphoblastic leukaemia antigen (CALLA)-associated neutral endopeptidase (3.4.24.11) in human chronic arthritis.
Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid.
Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients.
Structures of soluble rabbit neprilysin complexed with phosphoramidon or thiorphan.
The analgesic effects of morphine, but not those of the enkephalinase inhibitor thiorphan, are enhanced in arthritic rats.
Arthritis, Juvenile
Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients.
Arthritis, Rheumatoid
Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid.
Interaction analysis between BLK rs13277113 polymorphism and BANK1 rs3733197 polymorphism, MMEL1/TNFRSF14 rs3890745 polymorphism in determining susceptibility to rheumatoid arthritis.
Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?
Asthma
Airway neuropeptides and neutral endopeptidase in asthma.
Decreased serum neutral endopeptidase activity in children with bronchial asthma.
Effect of an inhaled neutral endopeptidase inhibitor, phosphoramidon, on baseline airway calibre and bronchial responsiveness to bradykinin in asthma.
Effect of inhaled atrial natriuretic peptide and a neutral endopeptidase inhibitor on histamine-induced bronchoconstriction.
Enhanced expression of neutral endopeptidase (NEP) in airway epithelium in biopsies from steroid- versus nonsteroid-treated patients with atopic asthma.
Epithelial modulation of cholinergic responses in rabbit trachea is partly due to neutral endopeptidase activity.
European drug market entries 2015 with new mechanisms of action.
Neutral endopeptidase inhibition with inhaled phosphoramidon: no effect on bronchial responsiveness to adenosine 5'-monophosphate (AMP) in asthma.
No effect of the oral neutral endopeptidase inhibitor candoxatril, on bronchomotor tone and histamine reactivity in asthma.
Regulation of airway neurogenic inflammation by neutral endopeptidase.
Role of neutral endopeptidase and angiotensin converting enzyme in asthma.
[Enkephalinase activity in the guinea pig model of asthma]
[Membrane metalloendopeptidase (CD10/CALLA): distribution, physiologic and pathophysiologic functions and its inhibitors]
Astrocytoma
Hydrolysis of atrial and brain natriuretic peptides by the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y.
Atherosclerosis
Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition.
Vascular neutral endopeptidase inhibition improves endothelial function and reduces intimal hyperplasia.
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
Atrial Fibrillation
Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney.
Key advances in clinical cardiology.
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018.
Bacterial Infections
[Biological properties of agents of bacterial infection in Hyacinthus orientalis Z. and Calla Z]
Blast Crisis
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Human leukemia-associated antigen: relation to a family of surface glycoproteins.
Leukemia-associated antigens in ALL.
Separation of lymphoid and myeloid blasts in the mixed blast crisis of chronic myelogenous leukemia: no evidence for Ig gene rearrangement in CALLA-positive blasts.
Bone Resorption
Inhibition of bone resorption in vitro by human enkephalinase (EC 3.4.24.11), a neutral metalloendopeptidase.
Borna Disease
Degradation of amyloid ? peptide by neprilysin expressed from Borna disease virus vector.
Bradycardia
Cardiovascular effects of nociceptin in unanesthetized mice.
Restorative effect of atrial natriuretic peptide or chronic neutral endopeptidase inhibition on blunted cardiopulmonary vagal reflexes in aged rats.
Brain Diseases
Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles.
Brain Injuries, Traumatic
A Neprilysin Polymorphism and Amyloid-beta Plaques Following Traumatic Brain Injury.
Breast Cyst
Angiotensin-converting enzyme and enkephalinase in human breast cyst fluid.
Neutral endopeptidase activity in breast cysts.
Breast Neoplasms
Defining central themes in breast cancer biology by differential proteomics: conserved regulation of cell spreading and focal adhesion kinase.
Endostatin and irradiation modifies the activity of ADAM10 and neprilysin in breast cancer cells.
Epigenetic suppression of neprilysin regulates breast cancer invasion.
On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer.
Thalidomide combined with irradiation alters the activity of two proteases.
Bronchial Hyperreactivity
Correlation between neutral endopetidase (NEP) 3.4.24.11 in serum and the degree of the bronchial hyperreactivity.
Effect of active sensitization on the bronchopulmonary responses to tachykinins in the guinea pig. Modulation by peptidase inhibitors.
Role of tachykinins and neutral endopeptidase in toluene diisocyanate-induced bronchial hyperresponsiveness in guinea pigs.
Bronchial Spasm
Augmentation of neurally evoked cholinergic bronchoconstrictor responses by prejunctional NK2 receptors in the guinea-pig.
Bronchitis, Chronic
Pre-protachykinin-A mRNA is increased in the airway epithelium of smokers with chronic bronchitis.
Burkitt Lymphoma
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Carcinogenesis
Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells.
Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia.
Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.
Carcinoma
Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo.
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.
CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides.
Characterization of the promoter region of the rat neprilysin gene.
Cigarette smoke condensate could promote human bronchial epithelial BEAS-2B cell migration through shifting neprilysin trafficking.
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.
Distinct patterns of endothelin axis expression in primary prostate cancer.
Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.
Expression and Regulatory Network Analysis of MiR-139-3p, a New Potential Serum Biomarker for Esophageal Squamous Cell Carcinoma Based on Bioinformatics Analysis.
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis.
Neuropeptide Levels as well as Neprilysin Activity Decrease in Renal Cell Carcinoma.
Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo.
Renal Cell Carcinoma Presenting as Pleural Effusion.
Utility of CD10 and RCCma in the diagnosis of metastatic conventional renal-cell adenocarcinoma by fine-needle aspiration biopsy.
Carcinoma, Hepatocellular
Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas.
Detection of neutral endopeptidase 24.11 (neprilysin) in human hepatocellular carcinomas by immunocytochemistry.
Ectopeptidases are differentially expressed in hepatocellular carcinomas.
Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival.
High concentration of neutral endopeptidase (enkephalinase E.C. 3.4.24.11) in a malignant tumor: rat hepatoma 3924A.
Increased expression of neprilysin (neutral endopeptidase 24.11) in rat and human hepatocellular carcinomas.
Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma.
Carcinoma, Non-Small-Cell Lung
Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer.
Carcinoma, Renal Cell
Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.
Neuropeptide Levels as well as Neprilysin Activity Decrease in Renal Cell Carcinoma.
Renal Cell Carcinoma Presenting as Pleural Effusion.
Carcinoma, Small Cell
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.
Cardiomegaly
B-type natriuretic Peptide and the right heart.
Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction.
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Effect on prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction.
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats.
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure.
Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
Cardiomyopathies
Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas' disease.
Effects of Angiotensin Receptor Neprilysin Inhibitors on Inducibility of Ventricular Arrhythmias in Rats with Ischemic Cardiomyopathy.
Cardiomyopathy, Hypertrophic
Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end?stage hypertrophic cardiomyopathy.
Cardiovascular Diseases
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
Bioinformatic analysis of the neprilysin (M13) family of peptidases reveals complex evolutionary and functional relationships.
Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1.
Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.
Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies.
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Dual-Acting Angiotensin Receptor-Neprilysin Inhibition.
Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure.
Neprilysin Inhibitors in Cardiovascular Disease.
Neutral endopeptidase and angiotensin-converting enzyme inhibitors increase nitric oxide production in isolated canine coronary microvessels by a kinin-dependent mechanism.
Neutral endopeptidase inhibition: the potential of a new therapeutic approach in cardiovascular disease evolves.
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
Omapatrilat. Bristol-Myers Squibb.
Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects.
Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.
Radiosynthesis of the 11 C-methyl derivative of LBQ657 for PET investigation of the neprilysin inhibitor sacubitril.
Receptor-based 3D-QSAR study for recognizing true binding mode of mercaptoacyldipeptides at the active site of neutral endopeptidase.
Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene.
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review.
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.
The Role of Neprilysin Inhibitors in Cardiovascular Disease.
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
[Protective role of neutral endopeptidase in cardiovascular diseases]
Catalepsy
Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors.
Cerebral Amyloid Angiopathy
Association of neprilysin polymorphism with cerebral amyloid angiopathy.
Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy.
Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.
Long-term neprilysin inhibition - implications for ARNIs.
Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy.
Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.
Neprilysin Protects against Cerebral Amyloid Angiopathy and A?-Induced Degeneration of Cerebrovascular Smooth Muscle Cells.
Chagas Disease
Amino-terminal fragment of C-type natriuretic peptide precursor and C-type natriuretic peptide do not correlate in patients with Chagas disease: role for neutral endopeptidase.
Cardioprotective effects of phosphoramidon on myocardial structure and function in murine Chagas' disease.
NT-proCNP And CNP Do Not Correlate In Patients With Chagas' Disease: Role For Neutral Endopeptidase.
Tissue Inhibitor of Metalloproteinase-1 Is Increased in Chagasic Cardiomyopathy.
Charcot-Marie-Tooth Disease
A Novel Mutation of the Membrane Metallo-Endopeptidase Gene Related to Late-Onset Hereditary Polyneuropathy: Case Report and Review of the Literature.
Cholangiocarcinoma
Overexpression of membrane metalloendopeptidase inhibits substance P-stimulation of cholangiocarcinoma growth.
Prognostic significance of the combined expression of neutral endopeptidase and dipeptidyl peptidase IV in intrahepatic cholangiocarcinoma patients after surgery resection.
Cholecystitis
Naloxone-reversible inhibition of gall-bladder mucosal fluid secretion in experimental cholecystitis in the cat by acetorphan, an enkephalinase inhibitor.
Cholecystitis, Acute
Naloxone-reversible inhibition of gall-bladder mucosal fluid secretion in experimental cholecystitis in the cat by acetorphan, an enkephalinase inhibitor.
Cholera
New drug targets for cholera therapy.
Cholestasis
Lack of hepatocellular CD10 along bile canaliculi is physiologic in early childhood and persistent in Alagille syndrome.
Neutral endopeptidase activity is not elevated in serum in children with cholestatic liver disease: a unique role of aminopeptidase-m in sequential hydrolysis of peptides.
Cholesteatoma
Altered regulation of cell surface peptidases in human cholesteatoma.
Choriocarcinoma
Neutral endopeptidase/CD10 expression during phorbol ester-induced differentiation of choriocarcinoma cells through the protein kinase C- and extracellular signal-regulated kinase-dependent signalling pathway.
Signal pathway involved in increased expression of neutral endopeptidase 24.11 by gonadotropin releasing hormone in choriocarcinoma cells.
Upregulation of neutral endopeptidase expression and enzymatic activity during the differentiation of human choriocarcinoma cells.
Cluster Headache
A genome-wide analysis in cluster headache points to neprilysin and PACAP receptor gene variants.
Coinfection
A Strategy for Generating a Broad-Spectrum Monoclonal Antibody and Soluble Single-Chain Variable Fragments against Plant Potyviruses.
First Report of Tomato spotted wilt virus and Impatiens necrotic spot virus in Slovenia.
First report of Tomato spotted wilt virus and Impatiens necrotic spot virus in Slovenia.
Colitis
Anti-Inflammatory Effect of Homo- and Heterodimers of Natural Enkephalinase Inhibitors in Experimental Colitis in Mice.
Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis.
Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P.
Colitis, Ulcerative
Expression of the common acute lymphoblastic leukaemia antigen (CALLA gp100) in the brush border of normal jejunum and jejunum of patients with coeliac disease.
Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease.
Profound loss of neprilysin accompanied by decreased levels of neuropeptides and increased CRP in ulcerative colitis.
Colonic Neoplasms
Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands.
Neutral endopeptidase (NEP) is differentially involved in biological activities and cell signaling of colon cancer cell lines derived from various stages of tumor development.
Neutral endopeptidase depletion decreases colon cancer cell proliferation and TGF-?1 synthesis in indirect co-cultures with normal colon fibroblasts.
Optimizing the Profile of [99mTc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors.
Colorectal Neoplasms
Neutral endopeptidase (NEP) inhibitors - thiorphan, sialorphin, and its derivatives exert anti-proliferative activity towards colorectal cancer cells in vitro.
Complex Regional Pain Syndromes
Lack of genetic association of neutral endopeptidase (NEP) with complex regional pain syndrome (CRPS).
Confusion
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Coronary Artery Disease
Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study.
Coronary Disease
Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure.
Cough
Characterization of increased cough sensitivity after antigen challenge in guinea pigs.
Effect of Qinbai Qingfei Concentrated Pellets on substance P and neutral endopeptidase of rats with post-infectious cough.
Enzymatic modulation of bronchoconstriction, gland secretion, plasma extravasation and cough.
Evidence for substance P as an endogenous substance causing cough in guinea pigs.
Inhalation of phosphoramidon, a neutral endopeptidase inhibitor, induces cough in awake guinea-pigs.
Neutral endopeptidase inhibitors potentiate substance P- and capsaicin-induced cough in awake guinea pigs.
Pharmacology of bradykinin evoked coughing in guinea pigs.
Recombinant human enkephalinase (neutral endopeptidase) prevents cough induced by tachykinins in awake guinea pigs.
COVID-19
Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target?
Corrigendum to "Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost" [Biochem. Pharmacol. 178 (2020) 114057].
Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.
New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19.
Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.
The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection.
The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.
The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.
Crohn Disease
Expression of the common acute lymphoblastic leukaemia antigen (CALLA gp100) in the brush border of normal jejunum and jejunum of patients with coeliac disease.
Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease.
Cushing Syndrome
Significance of renal kininases in patients with Cushing's syndrome.
Cystic Fibrosis
A comprehensive review of therapeutic approaches available for the treatment of cholera.
New drug targets for cholera therapy.
Cystitis, Interstitial
Activation of the kallikrein kinin system in interstitial cystitis.
Cytomegalovirus Infections
The etiology of congenital nephrotic syndrome: current status and challenges.
Death, Sudden, Cardiac
Sacubitril/Valsartan: potential treatment for paediatric heart failure.
Dehydration
Combined effects of water stress and high temperature on photosynthesis, nitrogen metabolism and lipid peroxidation of a perennial grass Leymus chinensis.
Dementia
Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database.
Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid-?42 Levels in Lewy Body Disease.
Neprylisin decreases uniformly in Alzheimer's disease and in normal aging.
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies.
Transducible P11-CNTF rescues the learning and memory impairments induced by amyloid-beta peptide in mice.
Dermatitis, Allergic Contact
Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis.
Diabetes Complications
Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases.
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Diabetes Mellitus
Current indications of plasma atrial natriuretic peptide measurements in human diseases.
Degradation of islet amyloid polypeptide by neprilysin.
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Effect of high glucose levels on amyloid ? production in retinas of spontaneous diabetes mellitus Otsuka Long-Evans Tokushima fatty rats.
New drugs: big changes in conservative heart failure therapy?
Diabetes Mellitus, Type 1
Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-? Alterations in a Monkey Model of Type 1 Diabetes.
Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment.
Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.
Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.
Diabetes Mellitus, Type 2
Degradation of islet amyloid polypeptide by neprilysin.
Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats.
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial.
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx.
Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
The Drosophila melanogaster Neprilysin Nepl15 is involved in lipid and carbohydrate storage.
Diabetic Cardiomyopathies
Histone Acetylation Regulates Natriuretic Peptides and Neprilysin Gene Expressions in Diabetic Cardiomyopathy and Nephropathy.
Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy.
Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
Diabetic Nephropathies
Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy.
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
Genetic and functional effects of membrane metalloendopeptidase on diabetic nephropathy development.
Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension.
Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment.
The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy.
Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy.
Diabetic Neuropathies
The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy.
Diabetic Retinopathy
Elevated neprilysin activity in vitreous of patients with proliferative diabetic retinopathy.
The changing features of serum adropin, copeptin, neprilysin and chitotriosidase which are associated with vascular endothelial function in type 2 diabetic retinopathy patients.
Down Syndrome
Accumulation of Insoluble Amyloid-? in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities.
Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques.
Drug-Related Side Effects and Adverse Reactions
Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril?+?valsartan: A pharmacovigilance study.
Dyslipidemias
Key advances in clinical cardiology.
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
Dyspnea
BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era.
Tachykinin-induced dyspnea in conscious guinea pigs.
Endometrial Neoplasms
Decreased expression of messenger RNAs encoding endothelin receptors and neutral endopeptidase 24.11 in endometrial cancer.
Imbalance between neutral endopeptidase 24.11 and endothelin-1 expression in human endometrial carcinoma.
Endometriosis
Expression of aminopeptidase N and neutral endopeptidase on the endometrial stromal cells in endometriosis and adenomyosis.
Enteritis
Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A.
Epilepsy
Possible long-lasting inhibition of converting enzyme by enalapril in human cerebrospinal fluid.
The levels of renin-angiotensin related components are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy.
Epstein-Barr Virus Infections
Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Esophageal Squamous Cell Carcinoma
Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis.
Essential Hypertension
Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.
Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension.
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension.
Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.
Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension.
Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension.
Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications.
Increased tissue neutral endopeptidase 24.11 activity in spontaneously hypertensive hamsters.
Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension.
Neprilysin Inhibitors and Bradykinin.
Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.
Familial Hypophosphatemic Rickets
cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone.
Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts.
New insights into the pathogenesis of inherited phosphate wasting disorders.
Fibroadenoma
Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast.
Gallstones
Evidence for oxidative stress in the gall bladder mucosa of gall stone patients.
Gastritis
Differential changes in Substance P, VIP as well as neprilysin levels in patients with gastritis or ulcer.
Gastritis, Atrophic
Common acute lymphoplastic leukemia antigen (CALLA) and intestinal metaplasia.
Gastroenteritis
Towards a human rotavirus disease model.
Gastrointestinal Diseases
Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.
Gestational Trophoblastic Disease
The expression and localization of neutral endopeptidase 24.11/CD10 in human gestational trophoblastic diseases.
Glioblastoma
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
Glioma
Activation of 5-HT2C Receptor Promotes the Expression of Neprilysin in U251 Human Glioma Cells.
Expression of cALLa/NEP on gliomas: a possible marker of malignancy.
Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells.
Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.
Involvement of endopeptidase-24.11 in degradation of substance P by glioma cells.
Glomerulonephritis
Common acute lymphoblastic leukemia antigen expression on visceral epithelial cells in several types of glomerulonephritis.
The Comparison of the Podocyte Expression of Synaptopodin, CR1 and Neprilysin in Human Glomerulonephritis: Could the Expression of CR1 be Clinically Relevant?
[The role of podocytes in normal glomerular function and in the pathogenesis of glomerulonephritis. Part II. Phenotypic and functional changes of podocytes in glomerulonephritis]
Glomerulonephritis, Membranous
ADVANCES IN MEMBRANOUS NEPHROPATHY : SUCCESS STORIES OF A LONG JOURNEY.
Anti-neutral endopeptidase, natriuretic peptides disarrangement, and proteinuria onset in membranous nephropathy.
Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy.
Computational prediction and experimental assessment of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from neutral endopeptidase.
Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies.
Hereditary axonal neuropathy related to MME gene mutation in a family with fetomaternal alloimmune glomerulonephritis.
Lessons from a rare disease: IgG subclass and disease severity in alloimmune antenatal membranous nephropathy.
Mechanisms of disease: Alloimmunization in renal diseases.
Mechanisms of immune-deposit formation and the mediation of immune renal injury.
Membranous glomerulopathy: the evolving story.
New insights into the pathogenesis of membranous glomerulonephritis.
Pathogenesis of membranous nephropathy: recent advances and future challenges.
Pathophysiological advances in membranous nephropathy: time for a shift in patient's care.
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies.
Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men.
[Anti-CD10 fetomaternal alloimmunisation]
[Idiopathic and secondary membranous nephropathies].
[The involvement of neprilysin in the pathogenesis of glomerulopathies]
Glucose Intolerance
Hypertension up to date: SPRINT to SPYRAL.
Gram-Negative Bacterial Infections
Lipopolysaccharide induces upregulation of neutral endopeptidase 24.11 on human neutrophils: involvement of the CD14 receptor.
Heart Diseases
Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs.
Heart Failure
? Sacubitril valsartan for heart failure.
A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload.
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study.
A Test in Context: Neprilysin: Function, Inhibition, and Biomarker.
Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt.
Acute hemodynamic, hormonal, and renal effects of neutral endopeptidase inhibition in ovine heart failure.
Acute natriuretic effect of fasidotrilat, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in rats with heart failure.
Altered serum levels of neprilysin in heart failure patients with reduced ejection fraction.
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.
Angiotensin 2 Type 1 Receptor Blockade with Neprilysin Inhibition for Chronic Heart Failure: A New Paradigm?
Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.
Angiotensin Neprilysin Inhibition for Patients With Heart Failure: What If Sacubitril/Valsartan Were a Treatment for Cancer?
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact.
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe.
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: The PRIME Study.
Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series.
Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction?- Baseline Characteristics and Treatment of PARALLEL-HF Trial.
Angiotensin receptor neprilysin inhibitors in older patients with heart failure.
Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
Angiotensin Receptor-Neprilysin Inhibition.
Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects.
Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies.
Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.
Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization.
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review.
Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure.
BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era.
Calcitonin gene-related peptide is not elevated in rat plasma by heart failure or by neutral endopeptidase inhibition.
Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition.
Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart.
Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure.
Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1.
Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Case of a patient with heart failure, dilated cardiomyopathy and atrial fibrillation treated with sacubitril/valsartan.
Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy.
Changes in QRS Duration Are Associated with a Therapeutic Response to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction.
Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
Chronic heart failure: what does the horizon look like?
Chronic kidney disease, heart failure and neprilysin inhibition.
Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients.
Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism.
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA).
Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study.
Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.
Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure.
Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies.
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.
Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II.
Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.
Comparison of 12-month kinetics of serum markers of fibrosis between treatment with angiotensin receptor neprilysin inhibitor (ARNI) and angiotensin converting enzyme inhibitor (ACE-I) in patients with heart failure with reduced ejection fraction.
Comparison of chronic neutral endopeptidase inhibition and furosemide in an ovine model of heart failure.
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure.
Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects.
Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan.
Correction.
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
Cost-Effectiveness of Earlier Transition to Angiotensin Receptor Neprilysin Inhibitor in Patients With Heart Failure and Reduced Ejection Fraction.
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
Critical angioedema induced by a renin angiotensin system blocker in the contemporary era of increasing heart failure: A case report and commentary.
Current role of neprilysin inhibitors in hypertension and heart failure.
Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG.
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy.
Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure.
Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.
Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients?
Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure.
Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Dual-Acting Angiotensin Receptor-Neprilysin Inhibition.
Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.
Effect of 24-hour blood pressure and heart rate on the prognosis of patients with reduced and midrange LVEF.
Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects?.
Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial.
Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure.
Effect of neutral endopeptidase inhibitor in rats with congestive heart failure.
Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor.
Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure.
Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction.
Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Effects of angiotensin receptor neprilysin inhibitor on renal function in patients with heart failure: a systematic review and meta-analysis.
Effects of Angiotensin-Neprilysin Inhibition in Canines with Experimentally Induced Cardiorenal Syndrome.
Effects of atriopeptidase inhibitor UK 79300 on left ventricular hydraulic load in patients with congestive heart failure.
Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure.
Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
Effects of omapatrilat on systemic arterial function in patients with chronic heart failure.
Effects of optimized heart failure medication on central sleep apnea with Cheyne-Stokes respiration pattern in chronic heart failure with reduced left-ventricular ejection fraction.
Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure.
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ?35.
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: A meta-analysis of randomized controlled trials.
Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: Let's leave the doubts behind.
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction?- Results From the PARALLEL-HF Study.
Efficacy and safety of sacubitril/valsartan in the treatment of heart failure: protocol for a systematic review incorporating unpublished clinical study reports.
Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure.
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Enhanced endothelin-1 degradation by intravenous morphine in patients with congestive heart failure: role of neutral endopeptidase 24.11.
Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications.
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure.
Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure.
Entresto, a new Panacea for Heart Failure?
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
European drug market entries 2015 with new mechanisms of action.
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials.
First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure.
First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
From kinetics to dynamics: are there differences between ACE inhibitors?
Future pharmacological therapy in hypertension.
Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats.
Heart failure with preserved ejection fraction: A dilemma in treatment options.
Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation.
Heart failure.
Heart failure: Neprilysin inhibition attenuates risk of hyperkalaemia in HFrEF.
How does neprilysin inhibition in heart failure work?
Hypertension - state of the art 2015.
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience.
Impact of prolonged utilization of neprilysin inhibition on the cognitive function of heart failure patients.
Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date.
Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction.
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
Increased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: effects on diastolic function.
Increased expression of renal neutral endopeptidase in severe heart failure.
Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure.
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
Influence of physician networks on prescribing a new ingredient combination in heart failure: a longitudinal claim data-based study.
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial.
Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure.
Inhibition of thermolysin and neutral endopeptidase 24.11 by a novel glutaramide derivative: X-ray structure determination of the thermolysin-inhibitor complex.
Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats.
Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure.
Is Entresto good for the brain?
It Is Not Taboo: Addressing Sexual Function in Adults with Congenital Heart Disease.
Key advances in clinical cardiology.
Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators.
LCZ696 ameliorates lipopolysaccharide-induced endothelial injury.
LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy.
Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure.
Management of Heart Failure Patient with CKD.
Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Medical Therapy of Heart Failure with Reduced Ejection Fraction-A Call for Comparative Research.
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Moderate potassium lowering effect of exogenous atrial natriuretic peptide in patients with acute heart failure.
Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
Natriuretic peptide-potentiating actions of neutral endopeptidase inhibition in rats with experimental heart failure.
Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage.
Neprilysin and Heart Failure: A "Sympathetic" Relationship?
Neprilysin and Natriuretic Peptide Regulation in Heart Failure.
Neprilysin as a Biomarker: Challenges and Opportunities.
Neprilysin in Heart Failure: From Oblivion to Center Stage.
Neprilysin Inhibition and the Treatment of Heart Failure: Recent Steps in the Right Direction.
Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
Neprilysin inhibition does not alter dynamic of proenkephalin-A 119-159 and pro-substance P in heart failure.
Neprilysin inhibition for heart failure.
Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism.
Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study.
Neprilysin inhibition--a novel therapy for heart failure.
Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.
Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
Neprilysin Inhibitors and Bradykinin.
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease.
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Response to the letter of Siniorakis et al.
Neprilysin inhibitors preserve renal function in heart failure.
Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost.
Neprilysin Plasma Concentrations: A New Prognostic Marker in Heart Failure.
Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Neprilysin: Biotarget and Biomarker in Heart Failure.
Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure.
Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure.
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.
New pharmacotherapy for heart failure with reduced ejection fraction.
New therapies for the treatment of congestive heart failure.
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
Novel therapies in acute and chronic heart failure.
NT-proCNP And CNP Do Not Correlate In Patients With Chagas' Disease: Role For Neutral Endopeptidase.
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Omapatrilat. Bristol-Myers Squibb.
Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats.
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Paramount Importance of Angiotensin Receptor Neprilysin Inhibitor in Heart Failure Management.
Pathophysiology of congestive heart failure: role of atrial natriuretic factor and therapeutic implications.
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Chronic Heart Failure.
Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects.
Pharmacology of heart failure: From basic science to novel therapies.
PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
PL 03-3 THE FUTURE DEVELOPMENT OF DRUG THERAPY FOR HYPERTENSION.
Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure.
Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF.
Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics?
Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure-A Comparative Review.
Potential Expanded Indications for Neprilysin Inhibitors.
Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.
Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure.
Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats.
Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience.
Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure: A Pilot Study.
Prolonged neutral endopeptidase inhibition in heart failure.
Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.
Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Pulmonary and renal neutral endopeptidase EC 3.4.24.11 in rats with experimental heart failure.
Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs.
Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling.
Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study.
Reduced ejection fraction heart failure - new data from multicenter studies and national registries regarding general and elderly populations: hopes and disappointments.
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Renal protective effect of sacubitril/valsartan in patients with heart failure.
Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure.
Renal response to candoxatrilat in patients with heart failure.
Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress.
Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
Role of Neprilysin Inhibitors in Heart Failure.
Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients.
Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.
Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report.
Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in db/db mice and KKAy mice compared with valsartan treatment.
Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment.
Sacubitril/valsartan: from a large clinical trial to clinical practice.
Sacubitril/Valsartan: From Clinical Trials to Real-world Experience.
Sacubitril/Valsartan: potential treatment for paediatric heart failure.
Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure.
Safety, Pharmacokinetics, and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects.
Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure.
Serum neprilysin and recurrent hospitalizations after acute heart failure.
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan.
Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?
Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization.
Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure.
Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study.
Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction.
Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction?
Soluble neprilysin does not correlate with prognosis in pulmonary hypertension.
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients.
Soluble neprilysin retains catalytic activity in heart failure.
Soluble Neprilysin, Corin Concentrations, and Clinical Outcome in Chronic Heart Failure: The miRNAs Role.
Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD).
Soluble neprilysin: A versatile biomarker for heart failure, cardiovascular diseases and diabetic complications-A systematic review.
Soluble Neprilysin?- Cardiac Function and Outcome in Hypertrophic Cardiomyopathy.
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure.
Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction.
Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.
Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics.
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.
The case for inhibiting p38 mitogen-activated protein kinase in heart failure.
The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure.
The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-? concentrations and clearance in the cynomolgus monkey.
The effect of LCZ696 on amyloid-? concentrations in cerebrospinal fluid in healthy subjects.
The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials.
The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations.
The Initial Evaluation and Management of a Patient with Heart Failure.
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure.
The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure.
The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure.
The Role of Neprilysin Inhibitors in the Treatment of Heart Failure with Preserved Ejection Fraction.
The role of neurohormonal activation in chronic heart failure and postmyocardial infarction.
The role of neutral endopeptidase in dogs with evolving congestive heart failure.
The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
The safety of sacubitril-valsartan for the treatment of chronic heart failure.
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
Treatment with angiotensin receptor neprilysin inhibitor for Taiwan heart failure patients: Rationale and baseline characteristics of the TAROT-HF study.
Update in recent clinical trials in heart failure.
Use of Angiotensin Receptor Neprilysin Inhibitor in Patients on Maintenance Hemodialysis with Reduced Cardiac Ejection Fraction, Real-World Experience From a Single Center.
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
Vasopeptidase inhibitors: will they have a role in clinical practice?
Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?
What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines.
[A novel therapy option for heart failure with dual angiotensin receptor and neprilysin inhibition].
[ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
[Bradykinin and ventricular function]
[Diuretics in the treatment of heart failure: current pathophysiological aspects]
[First Experience of Clinical Application of LCZ696 an AT1-angiotensin Receptors and Neprilysin Inhibitor in Patients With Chronic Heart Failure and Reduced Ejection Fraction].
[First Experience of Clinical Application of LCZ696--an AT1-angiotensin Receptors and Neprilysin Inhibitor--in Patients With Chronic Heart Failure and Reduced Ejection Fraction].
[From basic research to clinical results. The OVERTURE, ENABLE, and RENEWAL studies]
[Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF].
[Neprilysin inhibition and chronic kidney disease].
[New medical therapies for the treatment of systolic heart failure]
[New therapeutic era in heart failure with reduced ejection fraction: Which population of French patients is concerned?]
[Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure].
[The effect of angiotensin receptors and neprilysin inhibitors on myocardial remodeling in patients with chronic heart failure and atrial fibrillation].
[The relationship between natriuretic peptides and neprilysin pathways: the clinical simplification against the complexity of biological systems].
[Update on heart failure].
[«?ARNI?» (Angiotensin Receptor-Neprilysin Inhibitor): when, for whom and how?]
Heart Failure, Diastolic
Key advances in clinical cardiology.
Heart Failure, Systolic
A new class of drugs for systolic heart failure: The PARADIGM-HF study.
Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart failure.
Combined Inhibition of the Renin-Angiotensin System and Neprilysin Positively Influences Complex Mitochondrial Adaptations in Progressive Experimental Heart Failure.
Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice.
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Dual Angiotensin Receptor and Neprilysin Inhibition in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Morbidity and mortality in systolic heart failure also associated with raised serum neprilysin levels.
Morbidity and mortality in systolic heart failure also associated with raised serum neprilysin levels. Reply.
Update in recent clinical trials in heart failure.
Hematologic Neoplasms
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Leukemia-associated antigens in ALL.
Hepatoblastoma
Expression of cell adhesion molecules and common acute lymphoblastic leukaemia antigen in hepatoblastoma.
Hepatomegaly
Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Herpes Simplex
Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo.
Peptidomimetic design.
Hydronephrosis
Circulating adhesion molecules and neutral endopeptidase enzymuria in patients with urolithiasis and hydronephrosis.
Hyperaldosteronism
Renal kininases in primary aldosteronism.
Significance of renal kininases in patients with primary aldosteronism.
Hyperalgesia
Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin.
Methylprednisolone prevents nerve injury-induced hyperalgesia in neprilysin knockout mice.
Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide.
The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevention of the nociceptive response by on-site delivery of enkephalins.
Hypercalcemia
Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
Hypercholesterolemia
Decrease in enkephalinase A number in kidney membranes from hypercholesterolemic and hypertensive rats.
Hyperglycemia
Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice.
Hyperkalemia
Hyperkalemia in heart failure: current treatment and new therapeutic perspectives.
Management of Heart Failure Patient with CKD.
Moderate potassium lowering effect of exogenous atrial natriuretic peptide in patients with acute heart failure.
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Hypersensitivity, Immediate
Inhibition of neutral endopeptidase augments anaphylactic constriction of guinea pig tracheal smooth muscle.
Hypertension
A comparison of the hypotensive effects of Met-enkephalin in normotensive and spontaneously hypertensive rats.
Adults with Down syndrome challenge another paradigm: When aging no longer entails arterial hypertension.
AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension.
Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans.
Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.
Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies.
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.
Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1.
Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
Chronic endopeptidase inhibition in DOCA-salt hypertension: mechanism of cardiovascular protection.
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor I: assay in plasma of human volunteers by atmospheric-pressure ionisation mass-spectrometry following derivatisation with BF3-methanol.
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide fluorescence immunoassay (DELFIA).
Combinatorial inhibition of Angiotensin converting enzyme, Neutral endopeptidase and Aminopeptidase N by N-methylated peptides alleviates blood pressure and fibrosis in rat model of dexamethasone-induced hypertension.
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Combined neutral endopeptidase inhibitors.
Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.
Current role of neprilysin inhibitors in hypertension and heart failure.
Decrease in enkephalinase A number in kidney membranes from hypercholesterolemic and hypertensive rats.
Decreased Neprilysin and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease.
Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor.
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
Dual-Acting Angiotensin Receptor-Neprilysin Inhibition.
Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
Effects of acute and chronic blockade of neutral endopeptidase with Sch 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats.
Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension.
Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-? (A?) Plaque Load and A?-Synthesizing and A?-Degrading Enzymes in Frontal Cortex.
Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats.
Effects of omapatrilat on hemodynamics and safety in patients with heart failure.
Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension: A Randomized, Double-Blind, Placebo-Controlled Study.
Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (?65 Years) With Systolic Hypertension.
Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study.
Endopeptidase inhibition in angiotensin-induced hypertension. Effect of SCH 39370 in sheep.
Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension.
Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
First-in-Class Angiotensin Receptor Neprilysin Inhibitor in Heart Failure.
Hemodynamic and humoral effects of chronic treatment with the neutral endopeptidase inhibitor SCH 42495 in spontaneously hypertensive rats.
Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage site.
Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension.
Hypertension up to date: SPRINT to SPYRAL.
Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial.
Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension.
Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid.
Improved Insulin Sensitivity with Angiotensin Receptor Neprilysin Inhibition in Individuals with Obesity and Hypertension.
In silico based investigation of dynamic variations in neprilysin (NEP and NEP2) proteins for extracting the point of specificity.
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Key advances in clinical cardiology.
Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Natriuretic peptides and neprilysin inhibition in hypertension and hypertensive organ damage.
Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial.
New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
New drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition.
Omapatrilat. Bristol-Myers Squibb.
Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats.
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.
Peptide metabolism and the control of body fluid homeostasis.
Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol.
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Potentiation of brain natriuretic peptides by SQ 28,603, an inhibitor of neutral endopeptidase 3.4.24.11, in monkeys and rats.
Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study.
Reciprocal regulation of angiotensin converting enzyme and neutral endopeptidase in rats with experimental hypertension.
Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene.
Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
Role of neutral endopeptidase and angiotensin-converting enzyme in deoxycorticosterone acetate-salt hypertension.
Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.
Sampatrilat Shire.
Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease.
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.
The natriuretic peptides in hypertension.
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II-Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension.
Vasopeptidase inhibition for blood pressure control: emerging experience.
Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
Vasopeptidase inhibitors: will they have a role in clinical practice?
[Changing the paradigm: valsartan-inhibitor of neprilysin, a new dual-acting drug for arterial hypertension and heart failure].
[Dual inhibition of converting enzyme and neutral endopeptidase: a research new way in the field of hypertension]
[Membrane metalloendopeptidase (CD10/CALLA): distribution, physiologic and pathophysiologic functions and its inhibitors]
[OCTAVE and OPERA: discordance in hypertension therapy?]
Hypertension, Portal
Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats.
Hypertension, Pulmonary
Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via co-application of a neutral endopeptidase 24.11 inhibitor.
Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling.
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease.
Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia.
Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia.
Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia.
Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats.
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
Role of endogenous ANP in sodium excretion in rats with experimental pulmonary hypertension.
Soluble neprilysin does not correlate with prognosis in pulmonary hypertension.
The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Hypertension, Renovascular
Effects of Angiotensin II Type 1A Receptor on ACE2, Neprilysin and KIM-1 in Two Kidney One Clip (2K1C) Model of Renovascular Hypertension.
Hypertrophy, Left Ventricular
Chronic inhibition of neutral endopeptidase reduces left ventricular hypertrophy without changing blood pressure in spontaneously hypertensive rats.
Effects of SCH 42495, a neutral endopeptidase inhibitor, on cardiac function and mass in rats after repeated hyperbaric exposures.
The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats.
Hypertrophy, Right Ventricular
Neutral endopeptidase 24.11 inhibition reduces pulmonary vascular remodeling in rats exposed to chronic hypoxia.
Hypotension
Cardiovascular effects of nociceptin in unanesthetized mice.
Effect of pharmacological manipulation of endogenous atriopeptin activity on renal function.
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
Limitations of Sacubitril/Valsartan in the Management of Heart Failure.
Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N-terminal pro B-type natriuretic peptide levels.
Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis.
Infant, Newborn, Diseases
Neonatal disease in neutral endopeptidase alloimmunization: lessons for immunological monitoring.
Infections
A New Natural Host of Lisianthus necrosis virus in Taiwan
A New Natural Host of Lisianthus necrosis virus in Taiwan.
Airway hyper-responsiveness to neurokinin A and bradykinin following Mycoplasma pneumoniae infection associated with reduced epithelial neutral endopeptidase.
First Report of Carnation mottle virus in Calla lily (Zantedeschia spp.).
First report of Carnation mottle virus in Calla lily (Zantedeschia spp.).
First Report of Tomato spotted wilt virus and Impatiens necrotic spot virus in Slovenia.
First report of Tomato spotted wilt virus and Impatiens necrotic spot virus in Slovenia.
Genetic transformation of Ornithogalum via particle bombardment and generation of Pectobacterium carotovorum-resistant plants.
HIV-1 Tat inhibits neprilysin and elevates amyloid beta.
Human cytomegalovirus infection downregulates expression of the cellular aminopeptidases CD10 and CD13.
Identification of a Potyvirus Causing Latent Infection in Calla Lilies.
Identification of Turnip mosaic virus Isolates Causing Yellow Stripe and Spot on Calla Lily
Identification of Turnip mosaic virus Isolates Causing Yellow Stripe and Spot on Calla Lily.
Influenza infection causes airway hyperresponsiveness by decreasing enkephalinase.
Proteomic Analysis of Urine from California Sea Lions ( Zalophus californianus): A Resource for Urinary Biomarker Discovery.
The etiology of congenital nephrotic syndrome: current status and challenges.
The ultrastructure and permeability of tracheobronchial blood vessels in health and disease.
Infertility
Peptides in Seminal Fluid and Their Role in Infertility: A Potential Role for Opiorphin Inhibition of Neutral Endopeptidase Activity as a Clinically Relevant Modulator of Sperm Motility: A Review.
Inflammatory Bowel Diseases
Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Studies in inflammatory bowel disease and after in vitro exposure to different stimuli.
Anti-Inflammatory Effect of Homo- and Heterodimers of Natural Enkephalinase Inhibitors in Experimental Colitis in Mice.
Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease.
Influenza, Human
Influenza infection causes airway hyperresponsiveness by decreasing enkephalinase.
Insulin Resistance
Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.
Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-? Alterations in a Monkey Model of Type 1 Diabetes.
Effect of pioglitazone on altered expression of A? metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance.
Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats.
Improved Insulin Sensitivity with Angiotensin Receptor Neprilysin Inhibition in Individuals with Obesity and Hypertension.
Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia.
The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.
Iron Deficiencies
New drugs: big changes in conservative heart failure therapy?
[Heart failure and iron deficiency].
Keloid
Multi-Antigen Imaging Reveals Inflammatory DC, ADAM17 and Neprilysin as Effectors in Keloid Formation.
Keratoconus
Immunohistochemical Expression of Fas Ligand (FasL) and Neprilysin (Neutral endopeptidase/CD10) in Keratoconus.
Kidney Diseases
Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients.
Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
Urinary neprilysin for early detection of acute kidney injury after cardiac surgery: A prospective observational study.
Kidney Failure, Chronic
Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease.
Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure.
Inhibition of neutral endopeptidase stimulates renal sodium excretion in patients with chronic renal failure.
Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure.
Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
[Neprilysin inhibition and chronic kidney disease].
Kidney Neoplasms
Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.
Latent Infection
Identification of a Potyvirus Causing Latent Infection in Calla Lilies.
Identification of a potyvirus causing latent infection in calla lilies.
Leiomyoma
Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma.
Leptospirosis
Proteomic Analysis of Urine from California Sea Lions ( Zalophus californianus): A Resource for Urinary Biomarker Discovery.
Leukemia
A new tumor marker for bladder cancer.
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Acute leukemia with chromosome translocation (4;11): 7 new patients and analysis of 71 cases.
Acute leukemias with both myeloid and lymphoid surface markers. Cytoplasmic alpha-1-anti-chymotrypsin and alpha-1-anti-trypsin as possible indicators of early granulocytic differentiation.
Application of series of monoclonal antibodies against human white cell differentiation antigens and the common ALL antigen in the characterization of leukemia cells.
CALLA negative precursor B lymphoblastic leukemia with MLL gene translocation and an unusual FISH signal pattern.
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma.
Classification of human leukemia by membrane antigen analysis with xenoantisera.
Clinical and laboratory characteristics of acute leukemia with the 4;11 translocation.
Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura.
Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis.
Common acute lymphoblastic leukemia antigen expressed on leukemia and melanoma cell lines has neutral endopeptidase activity.
Comparative levels of CALLA/neutral endopeptidase on normal granulocytes, leukemic cells, and transfected COS-1 cells.
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Cytological and immunological study of 139 patients with acute leukemia.
Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA.
Detection of the common acute lymphoblastic leukemia antigen in the serum of leukemia patients.
Distribution and modulation of a human leukemia-associated antigen (CALLA).
Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction.
Expression of cALLa/NEP on gliomas: a possible marker of malignancy.
Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Immunophenotype of leukemic blasts with small peroxidase-positive granules detected by electron microscopy.
Immunophenotypic, cytogenetic and molecular investigations in two cases of CALLA positive acute myeloid leukemia.
In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells.
Leukemic myeloblasts expressing lymphoid markers.
Long-term culture of infant leukemia cells: dependence upon stromal cells from the bone marrow and bilineage differentiation.
Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.
Monoclonal antibodies to CALLA do not alter polymorphonuclear functions.
Monocyte markers and the common acute lymphoblastic leukemia antigen on chronic lymphocytic leukemia cells.
Occurrence of the common acute lymphoblastic leukemia antigen on blast cells of a patient with chronic myelomonocytic leukemia in non-lymphoid blastic phase.
Persistence of bone marrow lymphocytosis after induction treatment in common acute lymphoblastic leukemia. Marker analysis and significance.
Phorbol ester-mediated regulation of CD10/neutral endopeptidase transcripts in acute lymphoblastic leukemias.
Photoradiation methods for purging autologous bone marrow grafts.
Pseudomonas diarrhea in a child suffering from acute lymphatic leukemia.
Rabbit antiserum against a non-T, non-B leukemia cell line that carries the Ph1 chromosome (NALM-1): antibody specific to a non-T, non-B acute lymphoblastic leukemia antigen.
Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia.
Terminal deoxynucleotidyl transferase in acute leukemias by direct immunofluorescence.
Tonsillar mapping of determinants found on normal lymphoreticular (T,B,K, immature and macrophage) and myeloblastic leukemia cells.
Unique epitopes of common acute lymphoblastic leukemia antigen detected by new monoclonal antibodies.
[Acute mixed-cell human leukemia]
[Immunologic and enzymatic markers of acute infantile lymphoblastic leukemias]
[Preparation and cytotoxicity of McAb-HSA-MTX conjugates]
Leukemia, Lymphocytic, Chronic, B-Cell
B-cell neoplasms of the lymphocytic, lymphoplasmacytoid, and plasma cell types: immunohistologic analysis and clinical correlation.
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Monocyte markers and the common acute lymphoblastic leukemia antigen on chronic lymphocytic leukemia cells.
Pre-T chronic lymphocytic leukemia with common acute lymphoblastic leukemia antigen. A new immunologic variant.
[The presence of CALLA (common acute lymphoblastic leukemia antigens) and B-cell differentiation antigens in lymphocytic lymphoma]
Leukemia, Lymphoid
Difference between monoclonal antibodies against the common acute leukemia antigen from two different hybridomas.
Leukemia, Monocytic, Acute
Leukemic myeloblasts expressing lymphoid markers.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Human leukemia-associated antigen: relation to a family of surface glycoproteins.
Leukemia-associated antigens in ALL.
Separation of lymphoid and myeloid blasts in the mixed blast crisis of chronic myelogenous leukemia: no evidence for Ig gene rearrangement in CALLA-positive blasts.
Leukemia, Myeloid, Acute
Biologic and cytogenetic characteristics of leukemia in infants.
Detection of the common acute lymphoblastic leukemia antigen in the serum of leukemia patients.
Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies.
Immunophenotypic, cytogenetic and molecular investigations in two cases of CALLA positive acute myeloid leukemia.
Leukemia-associated antigens in ALL.
Secondary T-cell lymphoproliferation after marrow transplantation.
Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia.
Leukemia, Myelomonocytic, Chronic
Occurrence of the common acute lymphoblastic leukemia antigen on blast cells of a patient with chronic myelomonocytic leukemia in non-lymphoid blastic phase.
Leukemia, Plasma Cell
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
Leukemia, Promyelocytic, Acute
Photoradiation methods for purging autologous bone marrow grafts.
Lewy Body Disease
Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid-?42 Levels in Lewy Body Disease.
Lipoma
CD10 (neprilysin) expression: a potential adjunct in the distinction of hibernoma from morphologic mimics.
Liver Cirrhosis, Biliary
[Activity of neutral endopeptidase in serum of patients with primary biliary cirrhosis]
Liver Diseases
Neutral endopeptidase activity is not elevated in serum in children with cholestatic liver disease: a unique role of aminopeptidase-m in sequential hydrolysis of peptides.
Lung Diseases
Limitations of Sacubitril/Valsartan in the Management of Heart Failure.
Lung Injury
A possible involvement of oxidative lung injury in endotoxin-induced bronchial hyperresponsiveness to substance P in guinea pigs.
Alleviation of wood smoke-induced lung injury by tachykinin receptor antagonist and hydroxyl radical scavenger in guinea pigs.
Characterization of a soluble form of neutral endopeptidase-24.11 (EC 3.4.24.11) in human serum: enhancement of its activity in serum of underground miners exposed to coal dust particles.
Neutral endopeptidase determines the severity of pancreatitis-associated lung injury.
Recombinant human neutral endopeptidase ameliorates pancreatic elastase-induced lung injury.
Lung Neoplasms
Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo.
Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells.
Inactivation of neutral endopeptidase in lung cancer.
Low neutral endopeptidase levels in bronchoalveolar lavage fluid of lung cancer patients.
Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer.
Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
Lupus Erythematosus, Systemic
The etiology of congenital nephrotic syndrome: current status and challenges.
Lymphadenopathy
Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Lymphocytosis
Persistence of bone marrow lymphocytosis after induction treatment in common acute lymphoblastic leukemia. Marker analysis and significance.
Lymphoma
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
A variant Burkitt-type translocation (2p-;8q+) in a patient with diffuse large cell lymphoma.
Aggressive Diffuse Lymphoma Coexpressing NRAS p21 and C-erbB-2 (neu) Oncogene Products, and CALL A (CD 10).
An ultrastructural morphometric and immunophenotypic evaluation of Burkitt's and Burkitt's-like lymphomas.
Anatomical distribution of call antigen expressing cells in normal lymphatic tissue and in lymphomas.
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma.
CD10 is expressed in cutaneous clear cell lesions of different histogenesis.
Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura.
Common acute lymphoblastic leukemia-associated antigen (CALLA)-positive B cell lymphoma.
Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA.
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Follicular large cell lymphoma. An immunophenotype study.
Immunophenotypic characterization of follicle-center-cell-derived non-Hodgkin's lymphomas.
Leukemia derived from intermediately differentiated lymphocytic lymphoma.
Lymphocyte malignancy and chromosome 14: structural aberrations involving band q11.
Reactivity of Leu 1 and T101 monoclonal antibodies with B cell lymphomas (correlations with other immunological markers).
[Immunologic phenotypes of germinal center cell tumors]
Lymphoma, B-Cell
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma.
Photoradiation methods for purging autologous bone marrow grafts.
Lymphoma, Follicular
Common acute lymphoblastic leukemia-associated antigen (CALLA)-positive B cell lymphoma.
Follicular large cell lymphoma. An immunophenotype study.
Localization and imaging with radioiodine-labeled monoclonal antibodies in a xenogeneic tumor model for human B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Follicular large cell lymphoma. An immunophenotype study.
Lymphoma, Non-Hodgkin
Common acute lymphoblastic leukemia-associated antigen (CALLA)-positive B cell lymphoma.
Thiorphan stimulates clonal growth of GM-CFU in short-term cultures of bone marrow from a healthy donor and from patients with non-Hodgkin lymphoma.
Lymphoma, T-Cell
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Lymphoma, T-Cell, Peripheral
Lymphocyte malignancy and chromosome 14: structural aberrations involving band q11.
Macular Degeneration
Long-term neprilysin inhibition - implications for ARNIs.
Melanoma
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.
Common acute lymphoblastic leukemia antigen expressed on leukemia and melanoma cell lines has neutral endopeptidase activity.
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Degradation of alpha-melanocyte stimulating hormone (alpha-MSH) by CALLA/endopeptidase 24.11 expressed by human melanoma cells in culture.
Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin.
Expression of common acute lymphoblastic leukemia antigen (CALLA) on human malignant melanoma cell lines.
Expression of IL-2 receptors in human melanoma cells.
Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.
[Expression of neutral endopeptidase and motility-related protein-1 in cutaneous malignant melanoma]
Memory Disorders
?-Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease.
Drosophila neprilysin 1 rescues memory deficits caused by amyloid-? peptide.
Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.
Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit.
Peripheral delivery of a CNS targeted, metalo-protease reduces a? toxicity in a mouse model of Alzheimer's disease.
Menorrhagia
Endothelin and neutral endopeptidase in the endometrium of women with menorrhagia.
Mercury Poisoning
The etiology of congenital nephrotic syndrome: current status and challenges.
Metabolic Syndrome
Neprilysin, obesity and the metabolic syndrome.
Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome.
Nonclassical Axis of the Renin-Angiotensin System and Neprilysin: Key Mediators That Underlie the Cardioprotective Effect of PPAR-Alpha Activation during Myocardial Ischemia in a Metabolic Syndrome Model.
Vascular and neural dysfunctions in obese Zucker rats: effect of AVE7688.
Microphthalmos
Neprilysin, a novel target for ultraviolet B regulation of melanogenesis via melanocortins.
Migraine Disorders
Hypernociceptive syndromes and pharmacological inhibition of endogenous opioid degradation.
Miosis
Administration of recombinant enkephalinase (neutral endopeptidase) prevents capsaicin-induced miosis in the rabbit eye in vivo.
Recombinant enkephalinase effectively inhibits substance P-induced miosis in the rabbit eye cup model.
Mitral Valve Insufficiency
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: The PRIME Study.
Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
Monoclonal Gammopathy of Undetermined Significance
Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.
Multiple Myeloma
B-cell neoplasms of the lymphocytic, lymphoplasmacytoid, and plasma cell types: immunohistologic analysis and clinical correlation.
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Multiple myeloma: the relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype suppression.
Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.
Multiple Sclerosis
Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple sclerosis.
Muscle Weakness
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.
Muscular Diseases
Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle.
Mycoplasma Infections
Airway hyper-responsiveness to neurokinin A and bradykinin following Mycoplasma pneumoniae infection associated with reduced epithelial neutral endopeptidase.
Mycosis Fungoides
Mycosis fungoides of the larynx: case report and review of the literature.
Myocardial Infarction
Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats.
Bradykinin metabolism in rat hearts with left-ventricular hypertrophy following myocardial infarction.
Correction to: Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. A novel aspect of endothelium dysfunction.
Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction.
Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction.
Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.
Effect on prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction.
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Effects of Angiotensin Receptor Neprilysin Inhibitors on Inducibility of Ventricular Arrhythmias in Rats with Ischemic Cardiomyopathy.
Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression.
Effects of neutral endopeptidase 24.11 inhibition on myocardial infarct size and ischemic preconditioning in rabbits.
Ex vivo effects of an Oenothera paradoxa extract on the reactive oxygen species generation and neutral endopeptidase activity in neutrophils from patients after acute myocardial infarction.
Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats.
Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction.
Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
Inhibition of human neutrophils NEP activity, CD11b/CD18 expression and elastase release by 3,4-dihydroxyphenylethanol-elenolic acid dialdehyde, oleacein.
Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Intravenous morphine reduces plasma endothelin 1 concentration through activation of neutral endopeptidase 24.11 in patients with myocardial infarction.
Natriuretic peptide-potentiating actions of neutral endopeptidase inhibition in rats with experimental heart failure.
Neprilysin inhibitors and chest pain perception in acute myocardial infarction.
Neprilysin levels at the acute phase of ST-elevation myocardial infarction.
Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling.
Renal denervation ameliorates post-infarction cardiac remodeling in rats through dual regulation of oxidative stress in the heart and brain.
Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats.
Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction.
The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction.
Myocardial Ischemia
Nonclassical Axis of the Renin-Angiotensin System and Neprilysin: Key Mediators That Underlie the Cardioprotective Effect of PPAR-Alpha Activation during Myocardial Ischemia in a Metabolic Syndrome Model.
Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study.
Myocardial Stunning
Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction.
Myositis
Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis.
Myositis, Inclusion Body
Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fibres of inclusion body myositis.
Nasal Obstruction
Role of neutral endopeptidase and kininase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis.
Neoplasm Metastasis
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Ectopeptidases in tumour biology: a review.
Epigenetic suppression of neprilysin regulates breast cancer invasion.
Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis.
Neutral endopeptidase depletion decreases colon cancer cell proliferation and TGF-?1 synthesis in indirect co-cultures with normal colon fibroblasts.
Thalidomide combined with irradiation alters the activity of two proteases.
Neoplasms
"To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
(99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice.
A Japanese Burkitt's lymphoma with t(2;8) and EBNA.
A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis.
A monoclonal antibody to common acute lymphoblastic leukemia antigen (CALLA) and its expression on several human tumor cell lines.
A new tumor marker for bladder cancer.
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
Acute lymphoblastic leukemia presenting as nephromegaly in a child: A rare case report.
Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
Anatomical distribution of call antigen expressing cells in normal lymphatic tissue and in lymphomas.
Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo.
Autoimmunoregulation: differential modulation of CD10/neutral endopeptidase 24.11 by tumor necrosis factor and neuropeptides.
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
CD10 immunoreactivity in sarcomatoid carcinomas: comparison with true sarcomas.
Cell specific expression of CD10/neutral endopeptidase 24.11 gene in human prostatic tissue and cells.
Changes in cell-surface peptidase activity in papillary renal cell carcinoma.
Characterization of malignant and non-neoplastic cell phenotypes in highly malignant non-Hodgkin lymphomas.
Clinical relevance of neutral endopeptidase (NEP/CD10) in melanoma.
Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis.
Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair.
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.
Concise Review: Neutral Endopeptidase (CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms, and Cancer.
Concise Review: Neutral Endopeptidase (NEP/CD10): A Multifaceted Environment Actor in Stem Cells, Physiological Mechanisms and Cancer.
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Cytokines and glucocorticoids modulate human bronchial epithelial cell peptidases.
Dendrobiumpolysaccharides attenuate cognitive impairment in senescence-accelerated mouse prone 8 mice via modulation of microglial activation.
Differential diagnostic significance of epithelial and stromal CD10 expression in tumors of trichogenic origin.
Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin.
Ectoenzyme regulation by phenotypically distinct fibroblast sub-populations isolated from the human mammary gland.
Ectopeptidases in tumour biology: a review.
Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Enkephalinase activity in the intestinal epithelial cells of the fetus of 19 days and their immortalized and transformed counterparts the SLC-cell lines.
Epigenetic suppression of neprilysin regulates breast cancer invasion.
Epithelial-myoepithelial carcinoma of the minor salivary glands: immunohistochemical and morphological features.
Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.
Expression and Regulatory Network Analysis of MiR-139-3p, a New Potential Serum Biomarker for Esophageal Squamous Cell Carcinoma Based on Bioinformatics Analysis.
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Expression of the common acute lymphoblastic leukemia antigen (CD10) in mesenchymal tumors.
Future pharmacologic agents for treatment of heart failure in children.
High concentration of neutral endopeptidase (enkephalinase E.C. 3.4.24.11) in a malignant tumor: rat hepatoma 3924A.
Human leukemia-associated antigen: relation to a family of surface glycoproteins.
Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells.
Icariside II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced cognitive deficits in rats.
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid.
Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation.
In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
Increase of CALLA-positive stimulated lymphoid cells in transient erythroblastopenia of childhood.
Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia.
Interaction analysis between BLK rs13277113 polymorphism and BANK1 rs3733197 polymorphism, MMEL1/TNFRSF14 rs3890745 polymorphism in determining susceptibility to rheumatoid arthritis.
Involvement of hippocampal agmatine in ?1-42 amyloid induced memory impairment, neuroinflammation and BDNF signaling disruption in mice.
Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.
Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses.
Long-term neprilysin inhibition - implications for ARNIs.
Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?
Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.
Lymphokine-activated killer cytotoxicity in neonatal mononuclear cells: in vitro responses to tumor cell lines from pediatric solid tumors.
Marker turned target? A case to review neprilysin in ALL (or lessons learned at the American Association for Cancer Research Meetings, 2006).
Markers of multiple hematopoietic-cell lineages in multiple myeloma.
Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma.
Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.
Molecular interaction between arsenic hydrate microcrystals and the cell-surface endopeptidase CD10 (neprilysin) - A possible link to the development of renal and cutaneous malignancies upon occupational exposure to arsenic compounds?
Monocyte markers and the common acute lymphoblastic leukemia antigen on chronic lymphocytic leukemia cells.
Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2.
Neutral endopeptidase (NEP) inhibitors - thiorphan, sialorphin, and its derivatives exert anti-proliferative activity towards colorectal cancer cells in vitro.
Neutral endopeptidase (NEP) is differentially involved in biological activities and cell signaling of colon cancer cell lines derived from various stages of tumor development.
Neutral endopeptidase depletion decreases colon cancer cell proliferation and TGF-?1 synthesis in indirect co-cultures with normal colon fibroblasts.
Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma.
One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in Mice Treated with Entresto.
Opioids, Neutral Endopeptidase, its Inhibitors and Cancer: Is There a Relationship among them?
Overexpression of B7-H4 promotes renal cell carcinoma progression by recruiting tumor-associated neutrophils via upregulation of CXCL8.
Phenotypic changes in large cell transformation of small cell lymphoid malignancies.
Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.
Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.
Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
Radiosynthesis of the 11 C-methyl derivative of LBQ657 for PET investigation of the neprilysin inhibitor sacubitril.
Rapidly Growing Papillary Well-Differentiated Adenocarcinoma in a Patient With a Helicobacter pylori-Naive Gastric Mucosa.
Rational redesign of neutral endopeptidase binding to merlin and moesin proteins.
Rebamipide reduces amyloid-? 1-42 (A?42) production and ameliorates A?43-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells.
Regulatory role of membrane-bound peptidases in the progression of gynecologic malignancies.
Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.
Saccharide alterations in rat kidney associated with malignant transformation by injection of dimethylnitrosamine.
Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression.
Subpopulations of common acute lymphoblastic leukemia antigen-positive lymphoid cells in normal bone marrow identified by hematopoietic differentiation antigens.
Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients.
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN.
Telmisartan Protects Against Aluminum-Induced Alzheimer-like Pathological Changes in Rats.
The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients.
The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27).
The common acute lymphoid leukemia antigen on b cells of chronic lymphoid leukemia and non-Hodgkin's lymphoma.
Tumor formation by a human pre-B leukemia cell line in scid mice is enhanced by matrigel and is associated with induction of CD10 expression.
Tumour suppression through modulation of neprilysin signaling: A comprehensive review.
VEGF-, KIT protein- and neutral endopeptidase (NEP/CD10)-positive myofibroblasts-precursors of angiogenesis in chorioangiomas?
[99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models.
Nephrolithiasis
Possible biphasic changes of free radicals in ethylene glycol-induced nephrolithiasis in rats.
neprilysin deficiency
Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism.
Amyloid Beta annular protofibrils in cell processes and synapses accumulate with aging and Alzheimer-associated genetic modification.
Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo.
Loss of neprilysin alters protein expression in the brain of Alzheimer's disease model mice.
Metabolic regulation of brain Abeta by neprilysin.
Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease.
Neprilysin Deficiency Is Associated With Expansion of Islet ?-Cell Mass in High Fat-Fed Mice.
Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx.
Neprilysin deficiency-dependent impairment of cognitive functions in a mouse model of amyloidosis.
Neuralgia
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.
Preventive and alleviative effects of the dual enkephalinase inhibitor (Denki) PL265 in a murine model of neuropathic pain.
Neurobehavioral Manifestations
Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report.
Neuroblastoma
Altered expression of cell surface membrane antigens in a common acute lymphoblastic leukemia-associated antigen-expressing neuroblastoma cell line (SJ-N-CG) with morphological differentiation.
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
Determination of hypoxic effect on neprilysin activity in human neuroblastoma SH-SY5Y cells using a novel HPLC method.
Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes.
Enhanced neprilysin-mediated degradation of hippocampal A?42 with a somatostatin peptide that enters the brain.
Estrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin.
Hydrolysis of atrial and brain natriuretic peptides by the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y.
Hypoxia-inducible factor-1? mediates up-regulation of neprilysin by histone deacetylase-1 under hypoxia condition in neuroblastoma cells.
Induction of neutral endopeptidase (NEP) activity of SK-N-SH cells by natural compounds from green tea.
Induction of neutral endopeptidase and angiotensin-converting enzyme activity of SK-N-SH cells in vitro by quercetin and resveratrol.
Nobiletin Reduces Intracellular and Extracellular ?-Amyloid in iPS Cell-Derived Alzheimer's Disease Model Neurons.
Recombinant neutral endopeptidase-24.11 expressed in mouse neuroblastoma cells is associated with neurite membranes.
The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase.
The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction.
[DNA cytometry analysis in childhood tumors]
[Expression of neprilysin gene is associated with methylation and histone modification on promoter in mouse neuroblastoma Neuro-2a cells].
Neurodegenerative Diseases
Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA.
Determination of hypoxic effect on neprilysin activity in human neuroblastoma SH-SY5Y cells using a novel HPLC method.
Neprilysin protects human neuronal progenitor cells against impaired development caused by amyloid-beta peptide.
Neuroendocrine Tumors
Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase.
Neurogenic Inflammation
CD10/neutral endopeptidase inhibition augments pulmonary neuroendocrine cell hyperplasia in hamsters treated with diethylnitrosamine and hyperoxia.
Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase.
Inhibition of neutral endopeptidase (NEP) facilitates neurogenic inflammation.
Inhibition of neutral endopeptidase potentiates neurogenic inflammation in the rat trachea.
Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: Protection by substance P receptor blockade.
Modulation of neurogenic inflammation by neutral endopeptidase.
Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients.
Neurogenic inflammation of the rat trachea: fate of neutrophils that adhere to venules.
Neurogenic inflammation: with additional discussion of central and perceptual integration of nonneurogenic inflammation.
Neurogenic responses in rat lungs after nose-only exposure to diesel exhaust.
Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P.
Neutral endopeptidase and kininase II mediate glucocorticoid inhibition of neurogenic inflammation in the rat trachea.
Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections.
Neutral endopeptidase modulates neurogenic inflammation.
Neutral endopeptidase modulation of neurogenic inflammation in airways.
Regulation of airway neurogenic inflammation by neutral endopeptidase.
Regulation of neurogenic inflammation by neutral endopeptidase.
Substance P is a determinant of lethality in diet-induced hemorrhagic pancreatitis in mice.
The role of substance P in inflammatory disease.
[Neutral endopeptidase (NEP)--modulator of neurogenic inflammation]
[The role of enkephalinase (neutral endopeptidase) in neurogenic inflammation of the respiratory tract]
Neuroinflammatory Diseases
Augmentation of glucagon-like peptide-1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure.
Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.
Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats.
Neuroinflammation drives APOE genotype-dependent differential expression of neprilysin.
Obesity
Cardio- and Neurometabolic Adipobiology: Consequences and Implications for Therapy.
ED 05-4 NATRIURETIC PEPTIDES, METABOLIC SYNDROME AND HYPERTENSION: AN INTEGRATED VIEW.
Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity.
Emerging Role of Adipocyte Dysfunction in Inducing Heart Failure Among Obese Patients With Prediabetes and Known Diabetes Mellitus.
Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
Improved Insulin Sensitivity with Angiotensin Receptor Neprilysin Inhibition in Individuals with Obesity and Hypertension.
Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
Neprilysin, obesity and the metabolic syndrome.
Obesity and aging affects skeletal muscle renin-angiotensin system and myosin heavy chain proportions in pre-diabetic Zucker rats.
Obesity-related heart failure with preserved ejection fraction: new treatment strategies.
Reduction and fragmentation of elastic fibers in the skin of obese mice is associated with altered mRNA expression levels of fibrillin-1 and neprilysin.
Osteoarthritis
Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid.
Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?
Osteosarcoma
Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients.
Out-of-Hospital Cardiac Arrest
Serum neprilysin and the risk of death in patients with out-of-hospital cardiac arrest of non-traumatic origin.
Overweight
Low-fat hypocaloric diet reduces neprilysin in overweight and obese human subjects.
Pancreatic Neoplasms
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Pancreatitis
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
The role of neutral endopeptidase in caerulein-induced acute pancreatitis.
Pancreatitis, Chronic
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues.
Substance P and neprilysin in chronic pancreatitis.
Paraproteinemias
Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells.
Periodontal Diseases
In vitro study of gingival fibroblasts from normal and inflamed tissue: age-related responsiveness.
Peripheral Nervous System Diseases
Antiallodynic effects of a CCKB antagonist in rats with nerve ligation injury: role of endogenous enkephalins.
Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment.
Neutral endopeptidase activity is increased in the skin of subjects with diabetic ulcers.
Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone.
Phyllodes Tumor
Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast.
Plasmacytoma
B-cell neoplasms of the lymphocytic, lymphoplasmacytoid, and plasma cell types: immunohistologic analysis and clinical correlation.
Pleural Effusion
Renal Cell Carcinoma Presenting as Pleural Effusion.
Pneumonia
Amniotic sac infection syndrome features fetal lung neuroendocrine cell hyperfunction.
Pneumonia, Mycoplasma
Airway hyper-responsiveness to neurokinin A and bradykinin following Mycoplasma pneumoniae infection associated with reduced epithelial neutral endopeptidase.
Polyneuropathies
A Novel Mutation of the Membrane Metallo-Endopeptidase Gene Related to Late-Onset Hereditary Polyneuropathy: Case Report and Review of the Literature.
Charcot-Marie-Tooth disease type 2 caused by homozygous MME gene mutation superimposed by chronic inflammatory demyelinating polyneuropathy.
Long-term neprilysin inhibition - implications for ARNIs.
Rare Variants in MME, Encoding Metalloprotease Neprilysin, Are Linked to Late-Onset Autosomal-Dominant Axonal Polyneuropathies.
Pre-Eclampsia
Increased immunohistochemical expression of neutral metalloendopeptidase (enkephalinase; EC 3.4.24.11) in villi of the human placenta with pre-eclampsia.
Serum neprilysin levels are elevated in preeclampsia.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia.
Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia; experience at the National Cancer Institute, Cairo University, Egypt.
Differential prognosis detected by immunophenotyping in acute lymphoblastic leukemia of childhood with poor prognostic factors.
Leukemia in infants.
Lineage specific classification of leukaemia: results of the analysis of sixty cases of childhood leukaemia.
Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia.
[Immunophenotyping in diagnostic and classification of leukemia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A human retinoblastoma cell line expressing the common acute lymphoblastic leukemia antigen and displaying an unusual chromosome abnormality.
A monoclonal antibody to common acute lymphoblastic leukemia antigen (CALLA) and its expression on several human tumor cell lines.
A monoclonal antibody to common acute lymphoblastic leukemia antigen (neutral endopeptidase) immunostains senile plaques in the brains of patients with Alzheimer's disease.
A newly established human acute lymphoblastic leukemia cell line with characteristics of the earliest B-cell maturation.
A novel Japanese Burkitt's lymphoma cell line, P32/Ishida, with a new variant chromosomal translocation (2;14).
A subpopulation of lymph node B-CLL cells expresses the common acute lymphoblastic leukemia antigen.
Ability of human colonic epithelium to express the 4F2 antigen, the common acute lymphoblastic leukemia antigen, and the transferrin receptor. Studies in inflammatory bowel disease and after in vitro exposure to different stimuli.
Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.
Acute leukemia presenting with myeloid and lymphoid cell markers.
Acute leukemias associated with the 4;11 chromosome translocation have rearranged immunoglobulin heavy chain genes.
Acute leukemias with both myeloid and lymphoid surface markers. Cytoplasmic alpha-1-anti-chymotrypsin and alpha-1-anti-trypsin as possible indicators of early granulocytic differentiation.
Aggressive Diffuse Lymphoma Coexpressing NRAS p21 and C-erbB-2 (neu) Oncogene Products, and CALL A (CD 10).
Altered expression of cell surface membrane antigens in a common acute lymphoblastic leukemia-associated antigen-expressing neuroblastoma cell line (SJ-N-CG) with morphological differentiation.
Anatomical distribution of call antigen expressing cells in normal lymphatic tissue and in lymphomas.
Anti-CALLA antibodies identify unique antigens on lymphoid cells and granulocytes.
Antibody affinity may influence antigenic modulation of the common acute lymphoblastic leukemia antigen in vitro.
Antigenic heterogeneity of clones and subclones from human melanoma cell lines demonstrated by a panel of monoclonal antibodies and flow microfluorometry analysis.
Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies.
Antigenically defined subgroups of lymphoblastic lymphoma. Relationship to clinical presentation and biologic behavior.
Association of the Neprilysin gene with susceptibility to late-onset Alzheimer's disease.
Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections.
B-cell maturation stages of Burkitt's lymphoma cell lines according to Epstein-Barr virus status and type of chromosome translocation.
Biologic and prognostic significance of the presence of more than two mu heavy-chain genes in childhood acute lymphoblastic leukemia of B precursor cell origin.
CALLA negative precursor B lymphoblastic leukemia with MLL gene translocation and an unusual FISH signal pattern.
Calla positive acute lymphoblastic leukemia after etoposide-based therapy for Ewing's sarcoma.
CALLA-positive myeloma: an aggressive subtype with poor survival.
Can CD10 be used as a diagnostic marker in thyroid pathology?
CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma.
CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation.
CD10 immunohistochemical staining in urothelial neoplasms.
CD10 is expressed in cutaneous clear cell lesions of different histogenesis.
CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis.
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.
Cellular antigens in nephroblastoma: identification with monoclonal antibodies which recognize hemopoietic cells.
Changes in membrane enzymes and glycosphingolipids in lymphocytes from HIV-1--infected and noninfected intravenous drug users.
Characterisation of enkephalinase (EC 3.4.24.11) activity on various leukemic cells expressing the common acute lymphocytic leukemia antigen (CALLA).
Characterization of a monoclonal antibody (A12) that defines a human acute lymphoblastic leukemia-associated differentiation antigen.
Characterization of human mammary cell types in primary culture: immunofluorescent and immunocytochemical indicators of cellular heterogeneity.
Characterization of malignant and non-neoplastic cell phenotypes in highly malignant non-Hodgkin lymphomas.
Characterization of membrane vesicles circulating in the serum of patients with common acute lymphoblastic leukemia.
Characterization of thymocytes expressing the common acute lymphoblastic leukemia antigen.
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
Circulating CALLA-positive lymphocytes exhibit circadian rhythms in man.
Classification of human leukemia by membrane antigen analysis with xenoantisera.
Clinical and laboratory characteristics of acute leukemia with the 4;11 translocation.
Clinical features of common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma: report of four cases.
Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura.
Clonal B-cell proliferation in an infant with congenital HIV infection and immune thrombocytopenia.
Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis.
Common acute lymphoblastic leukemia antigen (CD10)-positive Sézary's syndrome.
Common acute lymphoblastic leukemia antigen expressed on leukemia and melanoma cell lines has neutral endopeptidase activity.
Common acute lymphoblastic leukemia antigen expression on visceral epithelial cells in several types of glomerulonephritis.
Common acute lymphoblastic leukemia antigen: partial characterization by in vivo labeling and isolation of its messenger RNA.
Common acute lymphoblastic leukemia characterized by four different DNA stemlines with heterogeneity in RNA content, antigen expression and sensitivity to chemotherapy.
Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase.
Comparative levels of CALLA/neutral endopeptidase on normal granulocytes, leukemic cells, and transfected COS-1 cells.
Comparison of the expression of terminal deoxynucleotidyl transferase and common acute lymphoblastic leukemia antigen in selected hematologic malignancies.
Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases.
Critical role for Nef in HIV-1-induced podocyte dedifferentiation.
Current research on immunopathology of melanoma: analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma.
Degradation of alpha-melanocyte stimulating hormone (alpha-MSH) by CALLA/endopeptidase 24.11 expressed by human melanoma cells in culture.
Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features.
Detection of neutral endopeptidase-24.11/CD10 by flow cytometry and photomicroscopy using a new fluorescent inhibitor.
Detection of the common acute lymphoblastic leukemia antigen in the serum of leukemia patients.
Development of [125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis".
Diagnosis and analysis of the clinical course of T-phenotype acute lymphoblastic leukemia.
Discrepancy between flow cytometric analyses of CALLA using two monoclonal antibodies.
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.
Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues.
Distribution of neutral endopeptidase activity in human blood leukocytes.
Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction.
Down-regulation and inactivation of neutral endopeptidase 24.11 (enkephalinase) in human neutrophils.
Dual expression of lymphoid/basophil markers on single blast cells transformed from chronic myeloid leukemia.
Effect of cocaine and morphine on neutral endopeptidase activity of human peripheral blood mononuclear cells cultured with lectins.
Effects of monoclonal antibodies raised against the common acute lymphoblastic leukemia antigen on endopeptidase-24.11 activity.
Elevated common acute lymphoblastic leukemia antigen expression in pediatric immune thrombocytopenic purpura.
Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement.
Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement.
Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.
Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines.
Endopeptidase-24.11 is suppressed in myelin-forming but not in non-myelin-forming Schwann cells during development of the rat sciatic nerve.
Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker.
Epithelial-myoepithelial carcinoma of the minor salivary glands: immunohistochemical and morphological features.
Establishment and characterization of a common acute lymphoblastic leukemia cell line with a deletion of chromosome 3 band q26.
Establishment and characterization of a new human Burkitt's lymphoma cell line (WSU-BL).
Establishment of a Ph1-positive human cell line (BV173).
Exon 16 del: a novel form of human neutral endopeptidase (CALLA).
Expression of cALLa/NEP on gliomas: a possible marker of malignancy.
Expression of CD10/neutral endopeptidase in normal and malignant tissues of the human stomach and colon.
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.
Expression of common acute lymphoblastic leukemia antigen (CALLA) on human malignant melanoma cell lines.
Expression of common acute lymphoblastic leukemia antigen (CD 10) by myelinated fibers of the peripheral nervous system.
Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells.
Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines.
Expression of the common acute lymphoblastic leukemia antigen (CD10) in mesenchymal tumors.
Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers.
Failure of B cells in common variable immunodeficiency to transit from proliferation to differentiation is associated with altered B cell surface-molecule display.
Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody.
Gastrointestinal Obstruction due to Solitary Lymph Node Recurrence of Alpha-Fetoprotein-Producing Gastric Carcinoma with Enteroblastic Differentiation.
Granulocytes and cultured human fibroblasts express common acute lymphoblastic leukemia-associated antigens.
Growth factor control of myoepithelial-cell differentiation in cultures of human mammary gland.
Heparin inhibition of antibody-dependent complement-mediated lysis.
Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma.
High FLT3 expression and IL10 (G1082A) polymorphism in poor overall survival in calla acute lymphoblastic leukemia.
Histogenesis of diffuse small cleaved cell lymphoma. An immunohistochemical and molecular genetic (bcl-2 gene) study with comparison to follicular small cleaved cell lymphoma and mantle zone lymphoma.
Histopathological and immunohistochemical characterization of spontaneously occurring uterine deciduomas in young adult rats.
Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics.
Human glioma cell lines expressing the common acute lymphoblastic leukemia antigen (cALLa) have neutral endopeptidase activity.
Human nasal mucosal neutral endopeptidase (NEP): location, quantitation, and secretion.
Hyperdiploidy of 54 chromosomes with double Ph1 chromosome in lymphoid chronic myelocytic leukemic blast crisis.
Identification and characterization of a unique subpopulation (CALLA/CD10/negative) of human neutrophils manifesting a heightened chemotactic response to activated complement.
Identification and cloning of a prethymic precursor T lymphocyte from a population of common acute lymphoblastic leukemia antigen (CALLA)-positive fetal bone marrow cells.
Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype.
Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma.
Identification of myoepithelial cells in human and rat breasts by anti-common acute lymphoblastic leukemia antigen antibody A12.
Immunocytochemical characterization and identification of SGE1, a rat glomerular epithelial cell line.
Immunocytochemical identification of cell types in human mammary gland: variations in cellular markers are dependent on glandular topography and differentiation.
Immunocytological and immunochemical analysis on the common acute lymphoblastic leukemia antigen (CALLA): evidence that CALLA on ALL cells and granulocytes are structurally related.
Immunodiagnosis of childhood ALL with monoclonal antibodies to myeloid and lymphoid associated antigens.
Immunoelectron microscopy studies on the modulation of common acute lymphoblastic leukemia antigen (CALLA) on NALM-6 cells: delineation of intracellular transport.
Immunohistochemical Expression of CD10 in Cutaneous Basal and Squamous Cell Carcinomas.
Immunohistochemical expression of CD10 in cutaneous basal and squamous cell carcinomas.
Immunohistochemical study of mantle zone lymphoma.
Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group Study.
Immunophenotype and cytochemical reactions of acute lymphoblastic leukemia in Thai children.
Immunophenotype of leukemic blasts with small peroxidase-positive granules detected by electron microscopy.
Immunophenotype of lymphoid cells in positive patch tests of allergic contact dermatitis.
Immunophenotypic characterization of follicle-center-cell-derived non-Hodgkin's lymphomas.
Impaired mammary development in tamoxifen-treated prepubertal heifers is associated with altered development and morphology of myoepithelial cells.
Improved detection of rare CALLA-positive cells in peripheral blood using multiparameter flow cytometry.
In vitro and in vivo cytotoxic activity of anti-human leukemia monoclonal antibodies SN5c and SN6 daunorubicin conjugates.
In vitro and in vivo properties of human/mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
Increase of neutral endopeptidase-24.11 with cellular density and enzyme modulation with an inhibitor on human Reh6 cell line.
Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia.
Increased expression of neprilysin (neutral endopeptidase 24.11) in rat and human hepatocellular carcinomas.
Increased serum neutral endopeptidase activity in acute renal allograft rejection.
Induction of B-lymphocyte antigens on the chronic myeloid leukemic cell line K562 using sodium butyrate.
Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Induction of HLA-DC/DS (LEU 10) antigen expression by human precursor B cell lines.
Induction of plasmacytoid differentiation by phorbol ester in B-cell lymphoma cell lines bearing 8;14 translocations.
Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo.
Interferon-induced changes in expression of antigens defined by monoclonal antibodies on malignant and nonmalignant mononuclear hematopoietic cells.
Intermediate lymphocytic lymphoma: an immunophenotypic study with comparison to small lymphocytic lymphoma and diffuse small cleaved cell lymphoma.
Isolation and characterization of adult mammary stem cells from breast cancer-adjacent tissues.
Isolation of pure populations of epithelial and myoepithelial cells from the normal human mammary gland using immunomagnetic separation with Dynabeads.
Isolation of simian virus 40-transformed human mammary epithelial stem cell lines that can differentiate to myoepithelial-like cells in culture and in vivo.
Karyotypic patterns in acute mixed lineage leukemia.
Leukocyte common antigen--a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: correlation with immunologic studies and ultrastructural localization.
Localization and imaging with radioiodine-labeled monoclonal antibodies in a xenogeneic tumor model for human B-cell lymphoma.
Long-term follow-up of 14 patients with philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission.
Low molecular weight B cell growth factor induces proliferation of human B cell precursor acute lymphoblastic leukemias.
Lymphocyte malignancy and chromosome 14: structural aberrations involving band q11.
Lymphoid progenitor cells in severe combined immunodeficiency.
Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.
Lymphoma cell line (FL-18) and Epstein-Barr virus-carrying cell line (FL-18-EB) obtained from a patient with follicular lymphoma: monoclonal derivation and different properties.
Malignant leukemic cell separation by iron colloid immunomagnetic adsorption.
Marked difference in the in vivo antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD10). Mechanisms involved in the differential activities of immunotoxins.
Markers of multiple hematopoietic-cell lineages in multiple myeloma.
Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro.
Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein.
Monoclonal antibodies to CALLA do not alter polymorphonuclear functions.
Monoclonal antibody 55 (CD10) and complement used for purging autologous bone marrow in common acute lymphoblastic leukemia.
Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
Monoclonal antibody-ricin conjugate cytotoxic to cells expressing the common acute lymphoblastic leukemia antigen (CALLA).
Monocyte markers and the common acute lymphoblastic leukemia antigen on chronic lymphocytic leukemia cells.
Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.
Murine common acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11). Molecular characterization, chromosomal localization, and modeling of the active site.
Myelomonocytic antigen positive multiple myeloma.
Myoepithelial cell differentiation markers in prepubertal bovine mammary gland: effect of ovariectomy.
Neuroblastoma presenting as acute lymphoblastic leukemia but correctly diagnosed after orbital fine-needle aspiration biopsy.
Neutral endopeptidase 24.11 and angiotensin converting enzyme like activity in CALLA positive and CALLA negative lymphoid cells.
Neutral endopeptidase modulates septic shock.
Neutral endopeptidase modulation of septic shock.
Neutral metalloendopeptidase associated with the smooth muscle cells of pregnant rat uterus.
Nonhuman primates express human leukemia-associated antigens.
Occurrence of the common acute lymphoblastic leukemia antigen on blast cells of a patient with chronic myelomonocytic leukemia in non-lymphoid blastic phase.
Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions.
p63 and CD10: Reliable Markers in Discriminating Benign Sclerosing Lesions From Tubular Carcinoma of the Breast?
Persistence of bone marrow lymphocytosis after induction treatment in common acute lymphoblastic leukemia. Marker analysis and significance.
Phenotypic changes in large cell transformation of small cell lymphoid malignancies.
Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.
Phorbol ester-induced differentiation of a non-T/non-B human leukemic cell line (REH) to macrophage-like cells.
Photoradiation methods for purging autologous bone marrow grafts.
Polymorphonuclear neutrophils express the common acute lymphoblastic leukemia antigen.
Pre-T chronic lymphocytic leukemia with common acute lymphoblastic leukemia antigen. A new immunologic variant.
Production of human-mouse chimeric antibody by high cell density perfusion culture.
Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Provocative pattern of rearrangements of the genes for the gamma and beta chains of the T-cell receptor in human leukemias.
Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA).
Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow.
Purine metabolism enzyme pattern, cytochemical characteristics and clinicopathologic features of CD10-positive childhood T-cell leukemia.
Quantitative analysis of a new marker for common acute lymphoblastic leukemia detected by two-dimensional electrophoresis.
Quantitative variation of the common acute lymphoblastic leukemia antigen (gp100) on leukemic marrow blasts.
Rabbit antiserum against a non-T, non-B leukemia cell line that carries the Ph1 chromosome (NALM-1): antibody specific to a non-T, non-B acute lymphoblastic leukemia antigen.
Rapidly Growing Papillary Well-Differentiated Adenocarcinoma in a Patient With a Helicobacter pylori-Naive Gastric Mucosa.
Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen.
Renal Cell Carcinoma Presenting as Pleural Effusion.
Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.
Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity.
Role of CD10 Marker in Differentiating Malignant Thyroid Neoplasms from Benign Thyroid Lesions (Immunohistochemical & Histopathological Study).
Secondary T-cell lymphoproliferation after marrow transplantation.
Separation of lymphoid and myeloid blasts in the mixed blast crisis of chronic myelogenous leukemia: no evidence for Ig gene rearrangement in CALLA-positive blasts.
Serotherapy of acute lymphoblastic leukemia with monoclonal antibody.
Shedding of the common acute lymphoblastic leukemia antigen (CALLA) by lymphoblastoid cell lines.
Significance of common acute lymphoblastic leukemia antigen (cALLA) positive cells in bone marrow of children off therapy in complete remission.
Similarity of TALLA-1, a T-cell acute lymphoblastic leukemia antigen, to GP37.
Somatic cell mutants resistant to ricin, diphtheria toxin, and to immunotoxins.
Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
Stages of renal ontogenesis identified by monoclonal antibodies reactive with lymphohemopoietic differentiation antigens.
Structure/function studies of the common acute lymphoblastic leukemia antigen (CALLA/CD10) expressed on human neutrophils.
Subpopulations of common acute lymphoblastic leukemia antigen-positive lymphoid cells in normal bone marrow identified by hematopoietic differentiation antigens.
Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and A2L/AH) with Epstein-Barr virus and the relationship to the C3d receptor.
Suppression of tumor growth by in vivo administration of a recombinant human-mouse chimeric monoclonal antibody.
The common acute lymphoblastic leukemia antigen (CD10)--emancipation from a functional enigma.
The common acute lymphoblastic leukemia antigen (neutral endopeptidase-3.4.24.11) gene is located on human chromosome 3.
The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27).
The expression of common acute lymphoblastic leukemia antigen by bile canaliculi.
The phenotype of the neoplastic cells of hairy cell leukemia studied with monoclonal antibodies.
Thiorphan stimulates clonal growth of GM-CFU in short-term cultures of bone marrow from a healthy donor and from patients with non-Hodgkin lymphoma.
TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia.
Tonsillar mapping of determinants found on normal lymphoreticular (T,B,K, immature and macrophage) and myeloblastic leukemia cells.
Ultrastructure of myeloma cells in patients with common acute lymphoblastic leukemia antigen (CALLA)-positive myeloma.
Undifferentiated leukemia of infancy with t(11:17) chromosomal rearrangement. Coexpressing myeloid and B cell restricted antigens.
Unique epitopes of common acute lymphoblastic leukemia antigen detected by new monoclonal antibodies.
Unusual presentation of common acute lymphoblastic leukemia antigen-positive extramedullary disease in childhood. Two patients with isolated masseter muscle involvement.
Use of monoclonal antibodies to identify cerebrospinal fluid lymphoblasts in children with acute lymphoblastic leukemia.
[A transient appearance of CALLA positive blastoid cells after allogeneic bone marrow transplantation in a patient with acute lymphoblastic leukemia]
[Analysis of newly established monoclonal antibodies against common acute lymphoblastic leukemia antigen]
[Characterization of murine monoclonal antibodies against the common acute leukemia antigen (CALLA)]
[DNA cytometry analysis in childhood tumors]
[Membrane metalloendopeptidase (CD10/CALLA): distribution, physiologic and pathophysiologic functions and its inhibitors]
[Monoclonal antibodies (NU-N1 and NU-N2) reactive with common acute lymphoblastic leukemia antigen]
[Monoclonal antibodies against surface antigens of lymphoblasts and blood cells or bone marrow recognize constituents of the human nephron]
[Multi-phenotype leukemia in children. Apropos of 18 cases]
[Neonatal acute leukemia: apropos of 7 cases]
[Neutral endopeptidase activity in human peripheral blood leukocytes]
[Preparation and cytotoxicity of McAb-HSA-MTX conjugates]
[The presence of CALLA (common acute lymphoblastic leukemia antigens) and B-cell differentiation antigens in lymphocytic lymphoma]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group Study.
Immunological subtypes of acute lymphoblastic leukemia in north India.
Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study.
Terminal deoxynucleotidyl transferase in acute leukemias by direct immunofluorescence.
Prediabetic State
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Prostatic Hyperplasia
Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.
Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase.
CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy.
Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase.
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays.
Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Expression and immunolocalisation of neutral endopeptidase in prostate cancer.
Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy.
Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer.
Identification and characterization of two androgen response regions in the human neutral endopeptidase gene.
Induction of neutral endopeptidase activity in PC-3 cells by an aqueous extract of Epilobium angustifolium L. and oenothein B.
Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.
Linkage and microarray analyses of susceptibility genes in ACI/Seg rats: a model for prostate cancers in the aged.
Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
Membrane metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells.
Methylation of the neutral endopeptidase gene promoter in human prostate cancers.
Multiple androgen response elements cooperate in androgen regulated activity of the type 1 neutral endopeptidase promoter.
Negative regulation of NEP expression by hypoxia.
Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression.
Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway.
Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.
Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.
Neutral endopeptidase is a myristoylated protein.
Neutral endopeptidase promotes phorbol ester-induced apoptosis in prostate cancer cells by inhibiting neuropeptide-induced protein kinase C delta degradation.
Neutral endopeptidase protein expression and prognosis in localized prostate cancer.
Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1beta with IL-1beta acting as a modulator of cellular differentiation.
The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells.
Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells.
Proteinuria
Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy.
Inhibition of Both Neutral Endopeptidase and Endothelin-Converting Enzyme by SLV306 Reduces Proteinuria and Urinary Albumin Excretion in Diabetic Rats.
The Anti-Fibrotic Effect of Mycophenolic Acid-Induced Neutral Endopeptidase.
Pruritus
Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors.
Pulmonary Arterial Hypertension
Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial.
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
Chronic obstructive pulmonary disease and sacubitril: explore the role of neprilysin before its inhibition.
Decreased Neprilysin and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease.
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease.
Neprilysin inhibitors as a new approach in the treatment of right heart failure in the course of chronic obstructive pulmonary disease. Response to the letter of Siniorakis et al.
Pulmonary Edema
Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.
Purpura, Thrombocytopenic, Idiopathic
Clinical significance of HLA-DR+, CD19+, CD10+ immature B-cell phenotype and CD34+ cell detection in bone marrow lymphocytes from children affected with immune thrombocytopenic purpura.
Elevated common acute lymphoblastic leukemia antigen expression in pediatric immune thrombocytopenic purpura.
Renal Insufficiency
Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2.
Renal Insufficiency, Chronic
Chronic kidney disease, heart failure and neprilysin inhibition.
Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients?
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Neprilysin Inhibition and Effects on Kidney Function and Surrogates of Cardiovascular Risk in Chronic Kidney Disease.
Neprilysin inhibition in chronic kidney disease.
Protection of kidney function and tissue integrity by pharmacologic use of natriuretic peptides and neprilysin inhibitors.
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
[Neprilysin inhibition and chronic kidney disease].
Reperfusion Injury
The effect of neprilysin and renin inhibition on the renal dysfunction following ischemia-reperfusion injury in the rat.
The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction.
Respiratory Distress Syndrome
Expression of neutral endopeptidase activity during clinical and experimental acute lung injury.
Neutral endopeptidase in serum samples from patients with adult respiratory distress syndrome. Comparison with angiotensin-converting enzyme.
Substance P and neutral endopeptidase in development of acute respiratory distress syndrome following fire smoke inhalation.
Respiratory Hypersensitivity
Airway hyper-responsiveness to neurokinin A and bradykinin following Mycoplasma pneumoniae infection associated with reduced epithelial neutral endopeptidase.
Respiratory Insufficiency
Effect of phosphoramidon - a selective enkephalinase inhibitor - on nociception and behaviour.
Respiratory Tract Infections
Neutral endopeptidase and neurogenic inflammation in rats with respiratory infections.
Retinoblastoma
A human retinoblastoma cell line expressing the common acute lymphoblastic leukemia antigen and displaying an unusual chromosome abnormality.
CD10 and CD44 genes of leukemic cells and malignant cell lines show no evidence of transformation-related alterations.
Rheumatic Diseases
Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients.
Rhinitis, Allergic
Role of neutral endopeptidase and kininase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis.
Rickets, Hypophosphatemic
Two novel variants of the PHEX gene in patients with X?linked dominant hypophosphatemic rickets and prenatal diagnosis for fetuses in these families.
Sarcoma, Ewing
Calla positive acute lymphoblastic leukemia after etoposide-based therapy for Ewing's sarcoma.
Scleroderma, Diffuse
Discrepant expression of neprilysin on fibroblasts in diffuse systemic sclerosis.
Seizures
Enkephalinase inhibition antagonizes the increased susceptibility to seizure induced by REM sleep deprivation.
Neuroblastoma presenting as acute lymphoblastic leukemia but correctly diagnosed after orbital fine-needle aspiration biopsy.
Sepsis
Changes in A-type natriuretic peptide and its receptors induced by a neutral endopeptidase inhibitor in a rat model of sepsis.
Shock, Cardiogenic
Impaired plasma B-type natriuretic peptide clearance in human septic shock.
Shock, Septic
Impaired plasma B-type natriuretic peptide clearance in human septic shock.
Neutral endopeptidase modulates septic shock.
Neutral endopeptidase modulation of septic shock.
Relationship between contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of rats in septic shock.
Sleep Apnea, Obstructive
Decrease in immunoreactive neutral endopeptidase in uvula epithelium of patients with obstructive sleep apnea.
Sleep Deprivation
Enkephalinase inhibition antagonizes the increased susceptibility to seizure induced by REM sleep deprivation.
REM sleep deprivation decreases the grooming and shaking behaviour induced by enkephalinase inhibitor or opiate withdrawal.
Spondylarthropathies
Enkephalinase: a physiologic neuroimmunomodulator detected in the synovial fluid.
ST Elevation Myocardial Infarction
Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction.
Stomach Neoplasms
Common acute lymphoplastic leukemia antigen (CALLA) and intestinal metaplasia.
Stroke
Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival.
Subarachnoid Hemorrhage
Attenuation of SAH-induced cerebral vasospasm by a selective ECE inhibitor.
Syphilis, Congenital
The etiology of congenital nephrotic syndrome: current status and challenges.
Tetanus
Families of zinc metalloproteases.
Thrombocytopenia
Elevated common acute lymphoblastic leukemia antigen expression in pediatric immune thrombocytopenic purpura.
Thrombosis
The etiology of congenital nephrotic syndrome: current status and challenges.
Toxoplasmosis, Congenital
The etiology of congenital nephrotic syndrome: current status and challenges.
Tuberculosis
Functional characterization of the Mycobacterium tuberculosis zinc metallopeptidase Zmp1 and identification of potential substrates.
Ureteral Obstruction
Renal responses to atrial natriuretic peptide are preserved in bilateral ureteral obstruction and augmented by neutral endopeptidase inhibition.
Urinary Bladder Neoplasms
A new tumor marker for bladder cancer.
Urolithiasis
Circulating adhesion molecules and neutral endopeptidase enzymuria in patients with urolithiasis and hydronephrosis.
Uterine Cervical Neoplasms
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
Ventricular Dysfunction, Left
Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs.
Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure.
The role of neurohormonal activation in chronic heart failure and postmyocardial infarction.
Virus Diseases
Pathophysiology of airway viral infections.
Viral infection increases contractile but not secretory responses to substance P in ferret trachea.
[The role of enkephalinase (neutral endopeptidase) in neurogenic inflammation of the respiratory tract]
Wilms Tumor
Cell differentiation in Wilms' tumor (nephroblastoma): an immunohistochemical study.
Critical role for Nef in HIV-1-induced podocyte dedifferentiation.